StemCell Therapy

New York, April 02, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Nerve Repair and Regeneration Industry" - https://www.reportlinker.com/p05799212/?utm_source=GNW 3%. The shifting dynamics supporting this growth makes it critical for businesses in this space to keep abreast of the changing pulse of the market. Poised to reach over US$11.8 Billion by the year 2025, Neurostimulation & Neuromodulation Devices will bring in healthy gains adding significant momentum to global growth.

- Representing the developed world, the United States will maintain a 11% growth momentum. Within Europe, which continues to remain an important element in the world economy, Germany will add over US$339.2 Million to the regions size and clout in the next 5 to 6 years. Over US$405.8 Million worth of projected demand in the region will come from Rest of Europe markets. In Japan, Neurostimulation & Neuromodulation Devices will reach a market size of US$527.3 Million by the close of the analysis period. As the worlds second largest economy and the new game changer in global markets, China exhibits the potential to grow at 16.1% over the next couple of years and add approximately US$1.4 Billion in terms of addressable opportunity for the picking by aspiring businesses and their astute leaders. Presented in visually rich graphics are these and many more need-to-know quantitative data important in ensuring quality of strategy decisions, be it entry into new markets or allocation of resources within a portfolio. Several macroeconomic factors and internal market forces will shape growth and development of demand patterns in emerging countries in Asia-Pacific, Latin America and the Middle East. All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.

- Competitors identified in this market include, among others,

Read the full report: https://www.reportlinker.com/p05799212/?utm_source=GNW

NERVE REPAIR AND REGENERATION MCP13MARKET ANALYSIS, TRENDS, AND FORECASTS, FEBRUARY 2CONTENTS

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. GLOBAL MARKET OVERVIEW Nerve Repair and Regeneration Market Set for a Rapid Growth Neurostimulation and Neuromodulation Devices: Largest Product Segment Biomaterials to Exhibit Rapid Growth Nerve Repair and Regeneration Market by Application US and Europe Dominate the Market, Asia-Pacific to Register the Fastest Growth

2. FOCUS ON SELECT PLAYERS Abbott Laboratories, Inc. (USA) AxoGen, Inc. (USA) Boston Scientific Corporation (USA) Integra LifeSciences Corporation (USA) LivaNova, PLC (UK) Medtronic plc (USA) NeuroPace, Inc. (USA) Nevro Corporation.(USA) Orthomed S.A.S. (France) Polyganics B.V. (The Netherlands) Stryker Corporation (U.S.) Synapse Biomedical Inc. (U.S.) Synovis Micro Companies Alliance, Inc. (USA)

3. MARKET TRENDS & DRIVERS High Incidence of Brain Disorders and Nerve Injuries: Primary Market Driver EXHIBIT 1: Annual Incidence of Adult-Onset Neurologic Disorders in the US EXHIBIT 2: Symptomatic Epilepsy Incidence by Type (2019): Percentage Share Breakdown of Congenital, Degenerative, Infective, Neoplastic, Trauma, and Vascular Epilepsy EXHIBIT 3: Global Alzheimer's Prevalence by Age Group EXHIBIT 4: Diagnosed Prevalence Cases of Parkinsons Disease Across Select Countries Classification of Nerve Injuries Recent Developments in Spinal Cord Injury Treatment Rising Geriatric Population and Subsequent Growth in Prevalence Of Neurological Disorders EXHIBIT 5: Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2and 2050 Intensified Research Activity Across Various Neural Disciplines Induces Additional Optimism Stem Cell Therapy: A Promising Avenue for Nerve Repair and Regeneration New Biomaterials Pave the Way for Innovative Neurodegeneration Therapies Role of Nerve Conduits in the Treatment of Peripheral Nerve Injury Innovative Nerve Conduits from Stryker Technological Advancements and Product Innovations - A Key Growth Driver Neurostimulation Allows Paralyzed People to Regain Leg Movement Neurostimulator to Treat Neurological Conditions Micro-Implantable Solution for Neurostimulation Parasym Device for Neurostimulation Boston Scientifics Spinal Cord Stimulation Improves Quality of Life Intellis Platform Presents Smallest Implantable Neurostimulator Innovation in Deep Brain Stimulation for Parkinsons Disease Innovations in Spinal Cord Stimulation for Pain Smart Neuromodulation: The Combination of AI and Neuromodulation Technologies New Dynamic Lead Interface Design for Neurostimulator Devices Wireless SCS Neuromodulation Therapy: An Alternative to Traditional SCS System Select Recent Approvals of Neuro-stimulation and Neuromodulation Devices Select Launches in Spinal Cord Stimulation (SCS) Market Select Launches in Deep Brain Stimulation (DBS) Market Select Neurostimulation Devices in Clinical Trials Select Neuromodulation Devices in Clinical Trials

4. GLOBAL MARKET PERSPECTIVE Table 1: Nerve Repair and Regeneration Global Market Estimates and Forecasts in US$ Thousand by Region/Country: 2018-2025 Table 2: Nerve Repair and Regeneration Global Retrospective Market Scenario in US$ Thousand by Region/Country: 2009-2017 Table 3: Nerve Repair and Regeneration Market Share Shift across Key Geographies Worldwide: 2009 VS 2019 VS 2025 Table 4: Neurostimulation & Neuromodulation Devices (Product) World Market by Region/Country in US$ Thousand: 2018 to 2025 Table 5: Neurostimulation & Neuromodulation Devices (Product) Historic Market Analysis by Region/Country in US$ Thousand: 2009 to 2017 Table 6: Neurostimulation & Neuromodulation Devices (Product) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025 Table 7: Biomaterials (Product) Potential Growth Markets Worldwide in US$ Thousand: 2018 to 2025 Table 8: Biomaterials (Product) Historic Market Perspective by Region/Country in US$ Thousand: 2009 to 2017 Table 9: Biomaterials (Product) Market Sales Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025 Table 10: Neurostimulation & Neuromodulation Surgeries (Application) Global Market Estimates & Forecasts in US$ Thousand by Region/Country: 2018-2025 Table 11: Neurostimulation & Neuromodulation Surgeries (Application) Retrospective Demand Analysis in US$ Thousand by Region/Country: 2009-2017 Table 12: Neurostimulation & Neuromodulation Surgeries (Application) Market Share Breakdown by Region/Country: 2009 VS 2019 VS 2025 Table 13: Neurorrhaphy (Application) Demand Potential Worldwide in US$ Thousand by Region/Country: 2018-2025 Table 14: Neurorrhaphy (Application) Historic Sales Analysis in US$ Thousand by Region/Country: 2009-2017 Table 15: Neurorrhaphy (Application) Share Breakdown Review by Region/Country: 2009 VS 2019 VS 2025 Table 16: Nerve Grafting (Application) Worldwide Latent Demand Forecasts in US$ Thousand by Region/Country: 2018-2025 Table 17: Nerve Grafting (Application) Global Historic Analysis in US$ Thousand by Region/Country: 2009-2017 Table 18: Nerve Grafting (Application) Distribution of Global Sales by Region/Country: 2009 VS 2019 VS 2025 Table 19: Stem Cell Therapy (Application) Sales Estimates and Forecasts in US$ Thousand by Region/Country for the Years 2through 2025 Table 20: Stem Cell Therapy (Application) Analysis of Historic Sales in US$ Thousand by Region/Country for the Years 2009 to 2017 Table 21: Stem Cell Therapy (Application) Global Market Share Distribution by Region/Country for 2009, 2019, and 2025 Table 22: Hospitals & Clinics (End-Use) Global Opportunity Assessment in US$ Thousand by Region/Country: 2018-2025 Table 23: Hospitals & Clinics (End-Use) Historic Sales Analysis in US$ Thousand by Region/Country: 2009-2017 Table 24: Hospitals & Clinics (End-Use) Percentage Share Breakdown of Global Sales by Region/Country: 2009 VS 2019 VS 2025 Table 25: Ambulatory Surgery Centers (End-Use) Worldwide Sales in US$ Thousand by Region/Country: 2018-2025 Table 26: Ambulatory Surgery Centers (End-Use) Historic Demand Patterns in US$ Thousand by Region/Country: 2009-2017 Table 27: Ambulatory Surgery Centers (End-Use) Market Share Shift across Key Geographies: 2009 VS 2019 VS 2025

III. MARKET ANALYSIS GEOGRAPHIC MARKET ANALYSIS UNITED STATES Table 28: United States Nerve Repair and Regeneration Market Estimates and Projections in US$ Thousand by Product: 2018 to 2025 Table 29: Nerve Repair and Regeneration Market in the United States by Product: A Historic Review in US$ Thousand for 2009-2017 Table 30: United States Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 31: United States Nerve Repair and Regeneration Latent Demand Forecasts in US$ Thousand by Application: 2018 to 2025 Table 32: Nerve Repair and Regeneration Historic Demand Patterns in the United States by Application in US$ Thousand for 2009-2017 Table 33: Nerve Repair and Regeneration Market Share Breakdown in the United States by Application: 2009 VS 2019 VS 2025 Table 34: United States Nerve Repair and Regeneration Latent Demand Forecasts in US$ Thousand by End-Use: 2018 to 2025 Table 35: Nerve Repair and Regeneration Historic Demand Patterns in the United States by End-Use in US$ Thousand for 2009-2017 Table 36: Nerve Repair and Regeneration Market Share Breakdown in the United States by End-Use: 2009 VS 2019 VS 2025 CANADA Table 37: Canadian Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Thousand by Product: 2018 to 2025 Table 38: Canadian Nerve Repair and Regeneration Historic Market Review by Product in US$ Thousand: 2009-2017 Table 39: Nerve Repair and Regeneration Market in Canada: Percentage Share Breakdown of Sales by Product for 2009, 2019, and 2025 Table 40: Canadian Nerve Repair and Regeneration Market Quantitative Demand Analysis in US$ Thousand by Application: 2018 to 2025 Table 41: Nerve Repair and Regeneration Market in Canada: Summarization of Historic Demand Patterns in US$ Thousand by Application for 2009-2017 Table 42: Canadian Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 Table 43: Canadian Nerve Repair and Regeneration Market Quantitative Demand Analysis in US$ Thousand by End-Use: 2to 2025 Table 44: Nerve Repair and Regeneration Market in Canada: Summarization of Historic Demand Patterns in US$ Thousand by End-Use for 2009-2017 Table 45: Canadian Nerve Repair and Regeneration Market Share Analysis by End-Use: 2009 VS 2019 VS 2025 JAPAN Table 46: Japanese Market for Nerve Repair and Regeneration: Annual Sales Estimates and Projections in US$ Thousand by Product for the Period 2018-2025 Table 47: Nerve Repair and Regeneration Market in Japan: Historic Sales Analysis in US$ Thousand by Product for the Period 2009-2017 Table 48: Japanese Nerve Repair and Regeneration Market Share Analysis by Product: 2009 VS 2019 VS 2025 Table 49: Japanese Demand Estimates and Forecasts for Nerve Repair and Regeneration in US$ Thousand by Application: 2018 to 2025 Table 50: Japanese Nerve Repair and Regeneration Market in US$ Thousand by Application: 2009-2017 Table 51: Nerve Repair and Regeneration Market Share Shift in Japan by Application: 2009 VS 2019 VS 2025 Table 52: Japanese Demand Estimates and Forecasts for Nerve Repair and Regeneration in US$ Thousand by End-Use: 2018 to 2025 Table 53: Japanese Nerve Repair and Regeneration Market in US$ Thousand by End-Use: 2009-2017 Table 54: Nerve Repair and Regeneration Market Share Shift in Japan by End-Use: 2009 VS 2019 VS 2025 CHINA Table 55: Chinese Nerve Repair and Regeneration Market Growth Prospects in US$ Thousand by Product for the Period 2018-2025 Table 56: Nerve Repair and Regeneration Historic Market Analysis in China in US$ Thousand by Product: 2009-2017 Table 57: Chinese Nerve Repair and Regeneration Market by Product: Percentage Breakdown of Sales for 2009, 2019, and 2025 Table 58: Chinese Demand for Nerve Repair and Regeneration in US$ Thousand by Application: 2018 to 2025 Table 59: Nerve Repair and Regeneration Market Review in China in US$ Thousand by Application: 2009-2017 Table 60: Chinese Nerve Repair and Regeneration Market Share Breakdown by Application: 2009 VS 2019 VS 2025 Table 61: Chinese Demand for Nerve Repair and Regeneration in US$ Thousand by End-Use: 2018 to 2025 Table 62: Nerve Repair and Regeneration Market Review in China in US$ Thousand by End-Use: 2009-2017 Table 63: Chinese Nerve Repair and Regeneration Market Share Breakdown by End-Use: 2009 VS 2019 VS 2025 EUROPE Table 64: European Nerve Repair and Regeneration Market Demand Scenario in US$ Thousand by Region/Country: 2018-2025 Table 65: Nerve Repair and Regeneration Market in Europe: A Historic Market Perspective in US$ Thousand by Region/Country for the Period 2009-2017 Table 66: European Nerve Repair and Regeneration Market Share Shift by Region/Country: 2009 VS 2019 VS 2025 Table 67: European Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Thousand by Product: 2018-2025 Table 68: Nerve Repair and Regeneration Market in Europe in US$ Thousand by Product: A Historic Review for the Period 2009-2017 Table 69: European Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 70: European Nerve Repair and Regeneration Addressable Market Opportunity in US$ Thousand by Application: 2018-2025 Table 71: Nerve Repair and Regeneration Market in Europe: Summarization of Historic Demand in US$ Thousand by Application for the Period 2009-2017 Table 72: European Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 Table 73: European Nerve Repair and Regeneration Addressable Market Opportunity in US$ Thousand by End-Use: 2018-2025 Table 74: Nerve Repair and Regeneration Market in Europe: Summarization of Historic Demand in US$ Thousand by End-Use for the Period 2009-2017 Table 75: European Nerve Repair and Regeneration Market Share Analysis by End-Use: 2009 VS 2019 VS 2025 FRANCE Table 76: Nerve Repair and Regeneration Market in France by Product: Estimates and Projections in US$ Thousand for the Period 2018-2025 Table 77: French Nerve Repair and Regeneration Historic Market Scenario in US$ Thousand by Product: 2009-2017 Table 78: French Nerve Repair and Regeneration Market Share Analysis by Product: 2009 VS 2019 VS 2025 Table 79: Nerve Repair and Regeneration Quantitative Demand Analysis in France in US$ Thousand by Application: 2018-2025 Table 80: French Nerve Repair and Regeneration Historic Market Review in US$ Thousand by Application: 2009-2017 Table 81: French Nerve Repair and Regeneration Market Share Analysis: A 17-Year Perspective by Application for 2009, 2019, and 2025 Table 82: Nerve Repair and Regeneration Quantitative Demand Analysis in France in US$ Thousand by End-Use: 2018-2025 Table 83: French Nerve Repair and Regeneration Historic Market Review in US$ Thousand by End-Use: 2009-2017 Table 84: French Nerve Repair and Regeneration Market Share Analysis: A 17-Year Perspective by End-Use for 2009, 2019, and 2025 GERMANY Table 85: Nerve Repair and Regeneration Market in Germany: Recent Past, Current and Future Analysis in US$ Thousand by Product for the Period 2018-2025 Table 86: German Nerve Repair and Regeneration Historic Market Analysis in US$ Thousand by Product: 2009-2017 Table 87: German Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 88: Nerve Repair and Regeneration Market in Germany: Annual Sales Estimates and Forecasts in US$ Thousand by Application for the Period 2018-2025 Table 89: German Nerve Repair and Regeneration Market in Retrospect in US$ Thousand by Application: 2009-2017 Table 90: Nerve Repair and Regeneration Market Share Distribution in Germany by Application: 2009 VS 2019 VS 2025 Table 91: Nerve Repair and Regeneration Market in Germany: Annual Sales Estimates and Forecasts in US$ Thousand by End-Use for the Period 2018-2025 Table 92: German Nerve Repair and Regeneration Market in Retrospect in US$ Thousand by End-Use: 2009-2017 Table 93: Nerve Repair and Regeneration Market Share Distribution in Germany by End-Use: 2009 VS 2019 VS 2025 ITALY Table 94: Italian Nerve Repair and Regeneration Market Growth Prospects in US$ Thousand by Product for the Period 2018-2025 Table 95: Nerve Repair and Regeneration Historic Market Analysis in Italy in US$ Thousand by Product: 2009-2017 Table 96: Italian Nerve Repair and Regeneration Market by Product: Percentage Breakdown of Sales for 2009, 2019, and 2025 Table 97: Italian Demand for Nerve Repair and Regeneration in US$ Thousand by Application: 2018 to 2025 Table 98: Nerve Repair and Regeneration Market Review in Italy in US$ Thousand by Application: 2009-2017 Table 99: Italian Nerve Repair and Regeneration Market Share Breakdown by Application: 2009 VS 2019 VS 2025 Table 100: Italian Demand for Nerve Repair and Regeneration in US$ Thousand by End-Use: 2018 to 2025 Table 101: Nerve Repair and Regeneration Market Review in Italy in US$ Thousand by End-Use: 2009-2017 Table 102: Italian Nerve Repair and Regeneration Market Share Breakdown by End-Use: 2009 VS 2019 VS 2025 UNITED KINGDOM Table 103: United Kingdom Market for Nerve Repair and Regeneration: Annual Sales Estimates and Projections in US$ Thousand by Product for the Period 2018-2025 Table 104: Nerve Repair and Regeneration Market in the United Kingdom: Historic Sales Analysis in US$ Thousand by Product for the Period 2009-2017 Table 105: United Kingdom Nerve Repair and Regeneration Market Share Analysis by Product: 2009 VS 2019 VS 2025 Table 106: United Kingdom Demand Estimates and Forecasts for Nerve Repair and Regeneration in US$ Thousand by Application: 2018 to 2025 Table 107: United Kingdom Nerve Repair and Regeneration Market in US$ Thousand by Application: 2009-2017 Table 108: Nerve Repair and Regeneration Market Share Shift in the United Kingdom by Application: 2009 VS 2019 VS 2025 Table 109: United Kingdom Demand Estimates and Forecasts for Nerve Repair and Regeneration in US$ Thousand by End-Use: 2to 2025 Table 110: United Kingdom Nerve Repair and Regeneration Market in US$ Thousand by End-Use: 2009-2017 Table 111: Nerve Repair and Regeneration Market Share Shift in the United Kingdom by End-Use: 2009 VS 2019 VS 2025 SPAIN Table 112: Spanish Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Thousand by Product: 2018 to 2025 Table 113: Spanish Nerve Repair and Regeneration Historic Market Review by Product in US$ Thousand: 2009-2017 Table 114: Nerve Repair and Regeneration Market in Spain: Percentage Share Breakdown of Sales by Product for 2009, 2019, and 2025 Table 115: Spanish Nerve Repair and Regeneration Market Quantitative Demand Analysis in US$ Thousand by Application: 2018 to 2025 Table 116: Nerve Repair and Regeneration Market in Spain: Summarization of Historic Demand Patterns in US$ Thousand by Application for 2009-2017 Table 117: Spanish Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 Table 118: Spanish Nerve Repair and Regeneration Market Quantitative Demand Analysis in US$ Thousand by End-Use: 2to 2025 Table 119: Nerve Repair and Regeneration Market in Spain: Summarization of Historic Demand Patterns in US$ Thousand by End-Use for 2009-2017 Table 120: Spanish Nerve Repair and Regeneration Market Share Analysis by End-Use: 2009 VS 2019 VS 2025 RUSSIA Table 121: Russian Nerve Repair and Regeneration Market Estimates and Projections in US$ Thousand by Product: 2018 to 2025 Table 122: Nerve Repair and Regeneration Market in Russia by Product: A Historic Review in US$ Thousand for 2009-2017 Table 123: Russian Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 124: Russian Nerve Repair and Regeneration Latent Demand Forecasts in US$ Thousand by Application: 2018 to 2025 Table 125: Nerve Repair and Regeneration Historic Demand Patterns in Russia by Application in US$ Thousand for 2009-2017 Table 126: Nerve Repair and Regeneration Market Share Breakdown in Russia by Application: 2009 VS 2019 VS 2025 Table 127: Russian Nerve Repair and Regeneration Latent Demand Forecasts in US$ Thousand by End-Use: 2018 to 2025 Table 128: Nerve Repair and Regeneration Historic Demand Patterns in Russia by End-Use in US$ Thousand for 2009-2017 Table 129: Nerve Repair and Regeneration Market Share Breakdown in Russia by End-Use: 2009 VS 2019 VS 2025 REST OF EUROPE Table 130: Rest of Europe Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Thousand by Product: 2018-2025 Table 131: Nerve Repair and Regeneration Market in Rest of Europe in US$ Thousand by Product: A Historic Review for the Period 2009-2017 Table 132: Rest of Europe Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 133: Rest of Europe Nerve Repair and Regeneration Addressable Market Opportunity in US$ Thousand by Application: 2018-2025 Table 134: Nerve Repair and Regeneration Market in Rest of Europe: Summarization of Historic Demand in US$ Thousand by Application for the Period 2009-2017 Table 135: Rest of Europe Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 Table 136: Rest of Europe Nerve Repair and Regeneration Addressable Market Opportunity in US$ Thousand by End-Use: 2018-2025 Table 137: Nerve Repair and Regeneration Market in Rest of Europe: Summarization of Historic Demand in US$ Thousand by End-Use for the Period 2009-2017 Table 138: Rest of Europe Nerve Repair and Regeneration Market Share Analysis by End-Use: 2009 VS 2019 VS 2025 ASIA-PACIFIC Table 139: Asia-Pacific Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Thousand by Region/Country: 2018-2025 Table 140: Nerve Repair and Regeneration Market in Asia-Pacific: Historic Market Analysis in US$ Thousand by Region/Country for the Period 2009-2017 Table 141: Asia-Pacific Nerve Repair and Regeneration Market Share Analysis by Region/Country: 2009 VS 2019 VS 2025 Table 142: Nerve Repair and Regeneration Market in Asia-Pacific by Product: Estimates and Projections in US$ Thousand for the Period 2018-2025 Table 143: Asia-Pacific Nerve Repair and Regeneration Historic Market Scenario in US$ Thousand by Product: 2009-2017 Table 144: Asia-Pacific Nerve Repair and Regeneration Market Share Analysis by Product: 2009 VS 2019 VS 2025 Table 145: Nerve Repair and Regeneration Quantitative Demand Analysis in Asia-Pacific in US$ Thousand by Application: 2018-2025 Table 146: Asia-Pacific Nerve Repair and Regeneration Historic Market Review in US$ Thousand by Application: 2009-2017 Table 147: Asia-Pacific Nerve Repair and Regeneration Market Share Analysis: A 17-Year Perspective by Application for 2009, 2019, and 2025 Table 148: Nerve Repair and Regeneration Quantitative Demand Analysis in Asia-Pacific in US$ Thousand by End-Use: 2018-2025 Table 149: Asia-Pacific Nerve Repair and Regeneration Historic Market Review in US$ Thousand by End-Use: 2009-2017 Table 150: Asia-Pacific Nerve Repair and Regeneration Market Share Analysis: A 17-Year Perspective by End-Use for 2009, 2019, and 2025 AUSTRALIA Table 151: Nerve Repair and Regeneration Market in Australia: Recent Past, Current and Future Analysis in US$ Thousand by Product for the Period 2018-2025 Table 152: Australian Nerve Repair and Regeneration Historic Market Analysis in US$ Thousand by Product: 2009-2017 Table 153: Australian Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 154: Nerve Repair and Regeneration Market in Australia: Annual Sales Estimates and Forecasts in US$ Thousand by Application for the Period 2018-2025 Table 155: Australian Nerve Repair and Regeneration Market in Retrospect in US$ Thousand by Application: 2009-2017 Table 156: Nerve Repair and Regeneration Market Share Distribution in Australia by Application: 2009 VS 2019 VS 2025 Table 157: Nerve Repair and Regeneration Market in Australia: Annual Sales Estimates and Forecasts in US$ Thousand by End-Use for the Period 2018-2025 Table 158: Australian Nerve Repair and Regeneration Market in Retrospect in US$ Thousand by End-Use: 2009-2017 Table 159: Nerve Repair and Regeneration Market Share Distribution in Australia by End-Use: 2009 VS 2019 VS 2025 INDIA Table 160: Indian Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Thousand by Product: 2018 to 2025 Table 161: Indian Nerve Repair and Regeneration Historic Market Review by Product in US$ Thousand: 2009-2017 Table 162: Nerve Repair and Regeneration Market in India: Percentage Share Breakdown of Sales by Product for 2009, 2019, and 2025 Table 163: Indian Nerve Repair and Regeneration Market Quantitative Demand Analysis in US$ Thousand by Application: 2018 to 2025 Table 164: Nerve Repair and Regeneration Market in India: Summarization of Historic Demand Patterns in US$ Thousand by Application for 2009-2017 Table 165: Indian Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 Table 166: Indian Nerve Repair and Regeneration Market Quantitative Demand Analysis in US$ Thousand by End-Use: 2to 2025 Table 167: Nerve Repair and Regeneration Market in India: Summarization of Historic Demand Patterns in US$ Thousand by End-Use for 2009-2017 Table 168: Indian Nerve Repair and Regeneration Market Share Analysis by End-Use: 2009 VS 2019 VS 2025 SOUTH KOREA Table 169: Nerve Repair and Regeneration Market in South Korea: Recent Past, Current and Future Analysis in US$ Thousand by Product for the Period 2018-2025 Table 170: South Korean Nerve Repair and Regeneration Historic Market Analysis in US$ Thousand by Product: 2009-2017 Table 171: Nerve Repair and Regeneration Market Share Distribution in South Korea by Product: 2009 VS 2019 VS 2025 Table 172: Nerve Repair and Regeneration Market in South Korea: Recent Past, Current and Future Analysis in US$ Thousand by Application for the Period 2018-2025 Table 173: South Korean Nerve Repair and Regeneration Historic Market Analysis in US$ Thousand by Application: 2009-2017 Table 174: Nerve Repair and Regeneration Market Share Distribution in South Korea by Application: 2009 VS 2019 VS 2025 Table 175: Nerve Repair and Regeneration Market in South Korea: Recent Past, Current and Future Analysis in US$ Thousand by End-Use for the Period 2018-2025 Table 176: South Korean Nerve Repair and Regeneration Historic Market Analysis in US$ Thousand by End-Use: 2009-2017 Table 177: Nerve Repair and Regeneration Market Share Distribution in South Korea by End-Use: 2009 VS 2019 VS 2025 REST OF ASIA-PACIFIC Table 178: Rest of Asia-Pacific Market for Nerve Repair and Regeneration: Annual Sales Estimates and Projections in US$ Thousand by Product for the Period 2018-2025 Table 179: Nerve Repair and Regeneration Market in Rest of Asia-Pacific: Historic Sales Analysis in US$ Thousand by Product for the Period 2009-2017 Table 180: Rest of Asia-Pacific Nerve Repair and Regeneration Market Share Analysis by Product: 2009 VS 2019 VS 2025 Table 181: Rest of Asia-Pacific Demand Estimates and Forecasts for Nerve Repair and Regeneration in US$ Thousand by Application: 2018 to 2025 Table 182: Rest of Asia-Pacific Nerve Repair and Regeneration Market in US$ Thousand by Application: 2009-2017 Table 183: Nerve Repair and Regeneration Market Share Shift in Rest of Asia-Pacific by Application: 2009 VS 2019 VS 2025 Table 184: Rest of Asia-Pacific Demand Estimates and Forecasts for Nerve Repair and Regeneration in US$ Thousand by End-Use: 2018 to 2025 Table 185: Rest of Asia-Pacific Nerve Repair and Regeneration Market in US$ Thousand by End-Use: 2009-2017 Table 186: Nerve Repair and Regeneration Market Share Shift in Rest of Asia-Pacific by End-Use: 2009 VS 2019 VS 2025 LATIN AMERICA Table 187: Latin American Nerve Repair and Regeneration Market Trends by Region/Country in US$ Thousand: 2018-2025 Table 188: Nerve Repair and Regeneration Market in Latin America in US$ Thousand by Region/Country: A Historic Perspective for the Period 2009-2017 Table 189: Latin American Nerve Repair and Regeneration Market Percentage Breakdown of Sales by Region/Country: 2009, 2019, and 2025 Table 190: Latin American Nerve Repair and Regeneration Market Growth Prospects in US$ Thousand by Product for the Period 2018-2025 Table 191: Nerve Repair and Regeneration Historic Market Analysis in Latin America in US$ Thousand by Product: 2009-2017 Table 192: Latin American Nerve Repair and Regeneration Market by Product: Percentage Breakdown of Sales for 2009, 2019, and 2025 Table 193: Latin American Demand for Nerve Repair and Regeneration in US$ Thousand by Application: 2018 to 2025 Table 194: Nerve Repair and Regeneration Market Review in Latin America in US$ Thousand by Application: 2009-2017 Table 195: Latin American Nerve Repair and Regeneration Market Share Breakdown by Application: 2009 VS 2019 VS 2025 Table 196: Latin American Demand for Nerve Repair and Regeneration in US$ Thousand by End-Use: 2018 to 2025 Table 197: Nerve Repair and Regeneration Market Review in Latin America in US$ Thousand by End-Use: 2009-2017 Table 198: Latin American Nerve Repair and Regeneration Market Share Breakdown by End-Use: 2009 VS 2019 VS 2025 ARGENTINA Table 199: Argentinean Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Thousand by Product: 2018-2025 Table 200: Nerve Repair and Regeneration Market in Argentina in US$ Thousand by Product: A Historic Review for the Period 2009-2017 Table 201: Argentinean Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 202: Argentinean Nerve Repair and Regeneration Addressable Market Opportunity in US$ Thousand by Application: 2018-2025 Table 203: Nerve Repair and Regeneration Market in Argentina: Summarization of Historic Demand in US$ Thousand by Application for the Period 2009-2017 Table 204: Argentinean Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 Table 205: Argentinean Nerve Repair and Regeneration Addressable Market Opportunity in US$ Thousand by End-Use: 2018-2025 Table 206: Nerve Repair and Regeneration Market in Argentina: Summarization of Historic Demand in US$ Thousand by End-Use for the Period 2009-2017 Table 207: Argentinean Nerve Repair and Regeneration Market Share Analysis by End-Use: 2009 VS 2019 VS 2025 BRAZIL Table 208: Nerve Repair and Regeneration Market in Brazil by Product: Estimates and Projections in US$ Thousand for the Period 2018-2025 Table 209: Brazilian Nerve Repair and Regeneration Historic Market Scenario in US$ Thousand by Product: 2009-2017 Table 210: Brazilian Nerve Repair and Regeneration Market Share Analysis by Product: 2009 VS 2019 VS 2025 Table 211: Nerve Repair and Regeneration Quantitative Demand Analysis in Brazil in US$ Thousand by Application: 2018-2025 Table 212: Brazilian Nerve Repair and Regeneration Historic Market Review in US$ Thousand by Application: 2009-2017 Table 213: Brazilian Nerve Repair and Regeneration Market Share Analysis: A 17-Year Perspective by Application for 2009, 2019, and 2025 Table 214: Nerve Repair and Regeneration Quantitative Demand Analysis in Brazil in US$ Thousand by End-Use: 2018-2025 Table 215: Brazilian Nerve Repair and Regeneration Historic Market Review in US$ Thousand by End-Use: 2009-2017 Table 216: Brazilian Nerve Repair and Regeneration Market Share Analysis: A 17-Year Perspective by End-Use for 2009, 2019, and 2025 MEXICO Table 217: Nerve Repair and Regeneration Market in Mexico: Recent Past, Current and Future Analysis in US$ Thousand by Product for the Period 2018-2025 Table 218: Mexican Nerve Repair and Regeneration Historic Market Analysis in US$ Thousand by Product: 2009-2017 Table 219: Mexican Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 220: Nerve Repair and Regeneration Market in Mexico: Annual Sales Estimates and Forecasts in US$ Thousand by Application for the Period 2018-2025 Table 221: Mexican Nerve Repair and Regeneration Market in Retrospect in US$ Thousand by Application: 2009-2017 Table 222: Nerve Repair and Regeneration Market Share Distribution in Mexico by Application: 2009 VS 2019 VS 2025 Table 223: Nerve Repair and Regeneration Market in Mexico: Annual Sales Estimates and Forecasts in US$ Thousand by End-Use for the Period 2018-2025 Table 224: Mexican Nerve Repair and Regeneration Market in Retrospect in US$ Thousand by End-Use: 2009-2017 Table 225: Nerve Repair and Regeneration Market Share Distribution in Mexico by End-Use: 2009 VS 2019 VS 2025 REST OF LATIN AMERICA Table 226: Rest of Latin America Nerve Repair and Regeneration Market Estimates and Projections in US$ Thousand by Product: 2018 to 2025 Table 227: Nerve Repair and Regeneration Market in Rest of Latin America by Product: A Historic Review in US$ Thousand for 2009-2017 Table 228: Rest of Latin America Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 229: Rest of Latin America Nerve Repair and Regeneration Latent Demand Forecasts in US$ Thousand by Application: 2018 to 2025 Table 230: Nerve Repair and Regeneration Historic Demand Patterns in Rest of Latin America by Application in US$ Thousand for 2009-2017 Table 231: Nerve Repair and Regeneration Market Share Breakdown in Rest of Latin America by Application: 2009 VS 2019 VS 2025 Table 232: Rest of Latin America Nerve Repair and Regeneration Latent Demand Forecasts in US$ Thousand by End-Use: 2018 to 2025 Table 233: Nerve Repair and Regeneration Historic Demand Patterns in Rest of Latin America by End-Use in US$ Thousand for 2009-2017 Table 234: Nerve Repair and Regeneration Market Share Breakdown in Rest of Latin America by End-Use: 2009 VS 2019 VS 2025 MIDDLE EAST Table 235: The Middle East Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Thousand by Region/Country: 2018-2025 Table 236: Nerve Repair and Regeneration Market in the Middle East by Region/Country in US$ Thousand: 2009-2017 Table 237: The Middle East Nerve Repair and Regeneration Market Share Breakdown by Region/Country: 2009, 2019, and 2025 Table 238: The Middle East Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Thousand by Product: 2018 to 2025 Table 239: The Middle East Nerve Repair and Regeneration Historic Market by Product in US$ Thousand: 2009-2017 Table 240: Nerve Repair and Regeneration Market in the Middle East: Percentage Share Breakdown of Sales by Product for 2009, 2019, and 2025 Table 241: The Middle East Nerve Repair and Regeneration Market Quantitative Demand Analysis in US$ Thousand by Application: 2018 to 2025 Table 242: Nerve Repair and Regeneration Market in the Middle East: Summarization of Historic Demand Patterns in US$ Thousand by Application for 2009-2017 Table 243: The Middle East Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 Table 244: The Middle East Nerve Repair and Regeneration Market Quantitative Demand Analysis in US$ Thousand by End-Use: 2to 2025 Table 245: Nerve Repair and Regeneration Market in the Middle East: Summarization of Historic Demand Patterns in US$ Thousand by End-Use for 2009-2017 Table 246: The Middle East Nerve Repair and Regeneration Market Share Analysis by End-Use: 2009 VS 2019 VS 2025 IRAN Table 247: Iranian Market for Nerve Repair and Regeneration: Annual Sales Estimates and Projections in US$ Thousand by Product for the Period 2018-2025 Table 248: Nerve Repair and Regeneration Market in Iran: Historic Sales Analysis in US$ Thousand by Product for the Period 2009-2017 Table 249: Iranian Nerve Repair and Regeneration Market Share Analysis by Product: 2009 VS 2019 VS 2025 Table 250: Iranian Demand Estimates and Forecasts for Nerve Repair and Regeneration in US$ Thousand by Application: 2018 to 2025 Table 251: Iranian Nerve Repair and Regeneration Market in US$ Thousand by Application: 2009-2017 Table 252: Nerve Repair and Regeneration Market Share Shift in Iran by Application: 2009 VS 2019 VS 2025 Table 253: Iranian Demand Estimates and Forecasts for Nerve Repair and Regeneration in US$ Thousand by End-Use: 2018 to 2025 Table 254: Iranian Nerve Repair and Regeneration Market in US$ Thousand by End-Use: 2009-2017 Table 255: Nerve Repair and Regeneration Market Share Shift in Iran by End-Use: 2009 VS 2019 VS 2025 ISRAEL Table 256: Israeli Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Thousand by Product: 2018-2025 Table 257: Nerve Repair and Regeneration Market in Israel in US$ Thousand by Product: A Historic Review for the Period 2009-2017 Table 258: Israeli Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 259: Israeli Nerve Repair and Regeneration Addressable Market Opportunity in US$ Thousand by Application: 2018-2025 Table 260: Nerve Repair and Regeneration Market in Israel: Summarization of Historic Demand in US$ Thousand by Application for the Period 2009-2017 Table 261: Israeli Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 Table 262: Israeli Nerve Repair and Regeneration Addressable Market Opportunity in US$ Thousand by End-Use: 2018-2025 Table 263: Nerve Repair and Regeneration Market in Israel: Summarization of Historic Demand in US$ Thousand by End-Use for the Period 2009-2017 Table 264: Israeli Nerve Repair and Regeneration Market Share Analysis by End-Use: 2009 VS 2019 VS 2025 SAUDI ARABIA Table 265: Saudi Arabian Nerve Repair and Regeneration Market Growth Prospects in US$ Thousand by Product for the Period 2018-2025 Table 266: Nerve Repair and Regeneration Historic Market Analysis in Saudi Arabia in US$ Thousand by Product: 2009-2017 Table 267: Saudi Arabian Nerve Repair and Regeneration Market by Product: Percentage Breakdown of Sales for 2009, 2019, and 2025 Table 268: Saudi Arabian Demand for Nerve Repair and Regeneration in US$ Thousand by Application: 2018 to 2025 Table 269: Nerve Repair and Regeneration Market Review in Saudi Arabia in US$ Thousand by Application: 2009-2017 Table 270: Saudi Arabian Nerve Repair and Regeneration Market Share Breakdown by Application: 2009 VS 2019 VS 2025 Table 271: Saudi Arabian Demand for Nerve Repair and Regeneration in US$ Thousand by End-Use: 2018 to 2025 Table 272: Nerve Repair and Regeneration Market Review in Saudi Arabia in US$ Thousand by End-Use: 2009-2017 Table 273: Saudi Arabian Nerve Repair and Regeneration Market Share Breakdown by End-Use: 2009 VS 2019 VS 2025 UNITED ARAB EMIRATES Table 274: Nerve Repair and Regeneration Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Thousand by Product for the Period 2018-2025 Table 275: United Arab Emirates Nerve Repair and Regeneration Historic Market Analysis in US$ Thousand by Product: 2009-2017 Table 276: Nerve Repair and Regeneration Market Share Distribution in United Arab Emirates by Product: 2009 VS 2VS 2025 Table 277: Nerve Repair and Regeneration Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Thousand by Application for the Period 2018-2025 Table 278: United Arab Emirates Nerve Repair and Regeneration Historic Market Analysis in US$ Thousand by Application: 2009-2017 Table 279: Nerve Repair and Regeneration Market Share Distribution in United Arab Emirates by Application: 2009 VS 2019 VS 2025 Table 280: Nerve Repair and Regeneration Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Thousand by End-Use for the Period 2018-2025 Table 281: United Arab Emirates Nerve Repair and Regeneration Historic Market Analysis in US$ Thousand by End-Use: 2009-2017 Table 282: Nerve Repair and Regeneration Market Share Distribution in United Arab Emirates by End-Use: 2009 VS 2VS 2025 REST OF MIDDLE EAST Table 283: Nerve Repair and Regeneration Market in Rest of Middle East: Recent Past, Current and Future Analysis in US$ Thousand by Product for the Period 2018-2025 Table 284: Rest of Middle East Nerve Repair and Regeneration Historic Market Analysis in US$ Thousand by Product: 2009-2017 Table 285: Rest of Middle East Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 286: Nerve Repair and Regeneration Market in Rest of Middle East: Annual Sales Estimates and Forecasts in US$ Thousand by Application for the Period 2018-2025 Table 287: Rest of Middle East Nerve Repair and Regeneration Market in Retrospect in US$ Thousand by Application: 2009-2017 Table 288: Nerve Repair and Regeneration Market Share Distribution in Rest of Middle East by Application: 2009 VS 2019 VS 2025 Table 289: Nerve Repair and Regeneration Market in Rest of Middle East: Annual Sales Estimates and Forecasts in US$ Thousand by End-Use for the Period 2018-2025 Table 290: Rest of Middle East Nerve Repair and Regeneration Market in Retrospect in US$ Thousand by End-Use: 2009-2017 Table 291: Nerve Repair and Regeneration Market Share Distribution in Rest of Middle East by End-Use: 2009 VS 2019 VS 2025 AFRICA Table 292: African Nerve Repair and Regeneration Market Estimates and Projections in US$ Thousand by Product: 2018 to 2025 Table 293: Nerve Repair and Regeneration Market in Africa by Product: A Historic Review in US$ Thousand for 2009-2017 Table 294: African Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 295: African Nerve Repair and Regeneration Latent Demand Forecasts in US$ Thousand by Application: 2018 to 2025 Table 296: Nerve Repair and Regeneration Historic Demand Patterns in Africa by Application in US$ Thousand for 2009-2017 Table 297: Nerve Repair and Regeneration Market Share Breakdown in Africa by Application: 2009 VS 2019 VS 2025 Table 298: African Nerve Repair and Regeneration Latent Demand Forecasts in US$ Thousand by End-Use: 2018 to 2025 Table 299: Nerve Repair and Regeneration Historic Demand Patterns in Africa by End-Use in US$ Thousand for 2009-2017 Table 300: Nerve Repair and Regeneration Market Share Breakdown in Africa by End-Use: 2009 VS 2019 VS 2025

IV. COMPETITION

Total Companies Profiled:

Read the full report: https://www.reportlinker.com/p05799212/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Excerpt from:
Global Nerve Repair and Regeneration Industry - GlobeNewswire

SOUTH PLAINFIELD, N.J., April 6, 2020 /PRNewswire/ -- Accurate Diagnostic Laboratories (ADL) and Rutgers University Cell & DNA Repository (RUCDR), through its Clinical Genomics Laboratory, are pleased to announce a joint mission aligning their efforts around improving testing capacity and service for the hospital inpatient population, health care providers and workers, first responders and patients.The relationship will facilitate providing high through-put and industry-leading turn around time for COVID-19 testing, also capitalizing on new methods to test. ADL and RUCDR have a long-standing relationship, where ADL performs diagnostic testing for RUCDR clinical trials, which aides in their data repository management. RUCDR, in conjunction with ADL's clinical client-base, fast-tracked the validation and verification of new testing methodologies, including saliva, for SARS-CoV-2 COVID-19. These alternate collection options will catapult the access of testing and screening to our most needed population."ADL's laboratory diagnostic capabilities, steeped in a tradition of offering the latest diagnostic technology offerings, is proud to expand our relationship with a local, world-renowned institution in Rutgers University Cell & DNA Repository laboratory.We want to do our mutual part to address the need for improved COVID-19 testing access, particularly for our front-line health care workers, hospital inpatient population, and first responders, by utilizing new collection and testing methods," says ADL's CEO, Rupen Patel.This is a game-changer for the market as "saliva testing will help with the global shortage of swabs for sampling and increase testing of patients, as it will not require health care professionals to collect samples," said Dr. Andrew Brooks, COO and director of technology development at RUCDR Infinite Biologics.He is also a professor in the Department of Genetics at Rutgers University-New Brunswick.As far as we know, we are the first and only laboratory to perform a significant validation and verification on multiple specimen types and not rely solely on the use of contrived samples.Accurate Diagnostic would like to formally thank those health care providers and health systems that assisted in the process to get this testing off the ground.

About Accurate Diagnostic Labs: Accurate Diagnostic Labs is one of the largest privately held, boutique, full-service clinical laboratories in the country.ADL, as a full-service core laboratory, proudly works with various entities on laboratory testing for clinical trial drug development and data repository in various market footprints to progress the field of disease state management and personalized medicine. With our local headquarters based in Central New Jersey, we pride ourselves in working with various healthcare corporations, institutions, health systems, and the local providers in the metropolitan area with the common goal of improving local and national healthcare.

Contact Information for ADL: For more information on ADL, please call at 732-839-3300 or visit online at http://www.accuratediagnosticlabs.com.

About RUCDR:RUCDR Infinite Biologics, which is part of Rutgers'Human Genetics Institute of New Jersey, is the world's largest university-based cell and DNA repository. Its mission is to understand the genetic causes of common, complex diseases and to discover diagnoses, treatments and cures for them. The organization collaborates with researchers in the public and private sectors throughout the world, providing the highest quality bio-banking services and biomaterials, as well as scientific and technical support.

Related Files

RUCDR ADL press release.docx

Related Images

rucdr.pngRUCDR

adl.pngADL

More:
Accurate Diagnostic Laboratories and Rutgers University Cell & DNA Repository Lab Work Together to Change the COVID-19 Testing Landscape - WFMZ...

Recently, as I was scheduling a routine procedure, the nurse asked for my fax number so she could send me the pre-op procedures. A fax machine in todays age? I was flabbergasted, as this was from an affiliate of one of the most sophisticated medical institutions in the United States, if not the world. I asked her to send me an email, and she indicated her systems were not equipped to do that but she might be able to scan the instructions and email them to me.

In light of the sweeping spread of Covid-19 and the increased pressure that has been and will continue to be brought to bear on the healthcare system, my experience becomes almost chilling.

As Cynthia Cox, director of the Peterson-Kaiser Health System Tracker recently commented to Vox: The coronavirus outbreak is already exposing inefficiencies and inequities in our health system, and it is likely to put much more strain on the system in the coming weeks.

And yet, we shouldnt need a pandemic to inform us that we need to bring our healthcare administration practices into modernity or to show investors the opportunity they have to bring about much-needed change.

My fax experience indicates that one major area to address is the antiquity of our healthcare system. In a time when our leaders and healthcare providers now face real concerns about Covid-19s potential to overwhelm our facilities and drain our resources, we have to wonder could the application of modern technology have improved our ability to handle a pandemic? The answer seems surely to be yes.

It is mind-boggling how healthcare practices stand in stark contrast to how advances in technology and science have dramatically improved diagnosing and treating a host of issues. In this context, profiting as an investor doesnt require one to be steeped in science or healthcare. In fact, one might argue that its best to come from the outside and apply a fresh perspective, as has been the case with many recent healthcare-focused entrepreneurs.

The marketplace for healthcare is massive; it literally applies to everyone. In the US alone, healthcare represents over $3 trillion or 18% of GDP. Its perplexing how an industry so large and all-consuming could be forced to rely on something as outdated as the fax machine.

The size, growth and dysfunction in healthcare lead me to believe there are few investment environments as fruitful as those concentrating on improving many key aspects of healthcare. There are enormous opportunities in biotechnology that are now possible due to massive leaps in computing power and cost, but I believe there are also equal opportunities to improve the actual processes associated with delivering healthcare. In the latter category, one is not required to have a deep science or medical aptitude to pursue or capitalize on.

It is these areas that I am most excited about, as they present the possibilities of applying otherwise-available technology to improving quality and reducing costs. According to Harry Glorikian in Moneyball Medicine, There are also substantial wastes and inefficiencies in healthcare factors that could be costing the United States $1 trillion. This includes costs related to overtreatment and unnecessary treatments, bloated administrative structures, fraud and overspending that result from an inability to effectively shop for best price. These gaps, failings and their corresponding enormities are an entrepreneurs and investors dream.

At its core, medicine is about gathering, deciphering and sharing information; information flows between patients and doctors, doctors and doctors, doctors and pharmacists, and so forth. This stream of facts, figures, and experiences ultimately results in the care of a patient.

Thanks to the transformative technologies weve seen in this young century, a transformation in the processing and dissemination of information has taken place, with more knowledge at our fingertips than imaginable just a few decades ago. From globe-spanning social connections to seemingly infinite encyclopedias to mobile connectivity and computing, several quantum leaps forward in technological capabilities now enable forward-thinkers to create a new world where price transparency and seamless collaboration are the norm.

Yet, despite the enormous advances in processing power and capability over the last 50 to 100 years, there remain many aspects of the actual process of practicing medicine that have barely evolved. While machines are unlikely to completely replace doctors anytime soon (or ever), the fact remains that there are a number of areas where the accurate, timely processing of information can dramatically improve patient well-being and ultimately the quality, cost and accessibility of both basic and complex healthcare.

Areas, like streamlining administrative processes, reducing redundancy or unnecessary procedures, or facilitating early and frequent interaction with medical professionals to treat conditions early or prevent them in the first place, are ripe for disruption from innovative approaches driven by technology. Investments in the following four categories are among the most obvious, lucrative and mutually advantageous areas where transformational change is possible and needed.

Medical Records: When you think about it, health records are actually incredibly inefficient. Not only do you have to fill out comprehensive medical questionnaires by handyou have to repeat this process every time you change doctors, switch insurance companies, or alter your records in any way. Not only is this a colossal waste of time, but I shudder to think of the details that are mistaken or forgotten and how that might impact optimal care.

Its not unreasonable to expect that, in todays digital age, ones health records should not only be easily accessible but also reside with the individual rather than being dispersed among the countless healthcare providers that the person is involved with. For too long, healthcare providers have been overly protective of this information often to the detriment of the patient. While some strides have been made in this area, substantial work remains to be done to create true interoperability among providers for a specific patient.

This efficiency will improve the process of caring for a patient and in many cases will improve outcomes because doctors will always instantly have comprehensive information at their fingertips. Medical histories, treatment plans or idiosyncratic issues will no longer slip through the cracks. The scope of this issue is highlighted when considering patients dealing with multiple complex issues that might involve numerous specialists and general practitioners. Moreover, a patients health record shouldnt be just for the provider, it should be user-friendly so that the patients themselves can monitor and manage their health.

Big players in tech are already making strides towards filling this customer service void, but the big gamechanger in this field still has yet to present itself. Its a completely realistic expectation that within the next decade well have moved onto quick, convenient, and secure medical records. There likely will be many players enabling the gathering, managing and sharing of patient information; however, the real transformational change will occur when the data contained in the health record is used to proactively diagnose and treat patients.

The Delivery of Care: Traditionally, the doctors office or hospitals was where medicine was almost exclusively practiced. Today, technology is enabling care for many basic issues to be delivered remotely to wherever the patient is. Telemedicine, or virtual care, utilizes technology so that doctors can seamlessly and, in some cases, instantly connect with patients to deliver care on demand.

The first iteration of this approach is traditional telemedicine, which uses video conferencing or a phone call to connect a doctor and patient. This approach is quickly and not unsurprisingly being usurped by asynchronous text on a smartphone how the world prefers to communicate where the doctors capabilities are being augmented by deep technology and AI. Providing easy and true on-demand accessibility for patients enables them to be treated early and often, which will unquestionably improve health outcomes. Pairing physicians with leading-edge technology can generate substantial efficiencies and leverage that, in turn, will reduce costs, increase quality and substantially expand those covered.

The flu offers a simple illustration of the power of technology that allows on-demand, remote care delivery: At the onset of symptoms, a patient can engage with a doctor and receive treatment. Instead of juggling their schedules or waiting to see a doctor which averages 29 days according to a Merritt Hawkins 2017 study the disease is treated promptly before it gets too far along. Furthermore, this remote treatment dramatically reduces contamination because there is no sitting in a waiting room or traveling often on mass transit to visit a doctor or urgent care center. In this scenario, everyone patient, provider, community and employer wins.

Similarly, technology is transforming how a patient is monitored either following a procedure or for chronic issues. In many cases, vital statistics can be monitored remotely and transmitted instantly to a care team. This enables patients to recover at home, which is more comfortable, cheaper, and comes without the infectious risks present at a hospital. For patients with chronic diseases, the ability to easily and accurately monitor factors like blood glucose levels, heart rate or blood pressure can be transformative in terms of managing a disease or preventing problems down the road. On a related note, technology-based tools can be employed to aid and ensure prescription adherence, which currently poses a huge and unnecessary cost to the system.

Healthcare delivery is only beginning to embrace the power of technology especially that of a smartphone to cut costs, increase access and improve quality. As I previously wrote, I believe that the power and ubiquity of smartphones will improve the worlds health on an individual and collective basis. Virtually every other aspect of our lives have been enhanced by this technology with the exception of primary healthcare.

Clinical Decision Support: The capabilities of AI, machine learning and big data can be applied to many aspects of healthcare in order to leverage a doctors time, improve quality and drive much needed efficiencies. Deep technology can now review images and tests faster and often more accurately than humans. The sheer mass and dispersion of medical information and current research makes it virtually impossible for a single doctor to always be up to speed. Technology that can foster the analysis and sharing of vast and complicated information will give doctors instant access to the plethora of research studies and clinical trials that might be relevant to their patients. Using technology to quickly and accurately identify and process information on a clients behalf will only improve care and drive down costs.

Precision Medicine / Personalized Diagnoses: Given the powerful computers at our disposal, it is easy to envision how we could use computers to aid decision-making, plugging in numerous permutations, conditions, and individual attributes unique to patients in order to determine the problems at hand and the optimal treatment plan. For example, for a prescription one will no longer need to rely on the catch all adult dosage and can instead determine the best amount for each patient based on their unique composition and metabolism.

Personalizing diagnoses is where AI is beginning to show real promise. Researchers have developed the technology for identifying heart disease, lung cancer and eye maladies with machine learning, and theyre only getting started. Even more cutting-edge is where a patients genome is analyzed to determine precisely the diagnosis and corresponding treatment plan. This capability is still in its infancy and only possible due to the advancements and price reductions in computing power.

Healthcare is ripe for the benefits technology affords and, as the responses and capabilities relating to Covid-19 demonstrates, desperately needs an update. Relative to other areas, I think the aforementioned categories might be low hanging fruit and hence represent significant investment potential. What I find particularly exciting is that the space is so large and in such desperate need that there will be a wide array of places to invest with potentially several players in each area. Fields such as Artificial Intelligence, Data Management and Cloud Computing offer much promise when applied to healthcare, especially in disrupting several areas that suffer from stagnation and lack of development. These applications will benefit doctors and patients alike while concurrently offering very attractive returns to the investors and entrepreneurs behind the companies. Lastly, and equally compelling, is that an investment that helps improve healthcare provides a greater good by enhancing lives and benefiting communities.

Photo: JamesBrey, Getty Images

Go here to see the original:
Is there a better market to invest in than healthcare? - MedCity News

DUBLIN, April 6, 2020 /PRNewswire/ -- The "Global Minimally Invasive Biopsy Technologies Market: Focus on Liquid Biopsy, Optical Biopsy, and Brush Biopsy, Pigmented Lesion Assays, and Breath Biopsy, Regulatory Scenario, Therapeutic Application, Competitive Landscape,18 Countries' Data - Analysis and Forecast, 2019-2030" report has been added to ResearchAndMarkets.com's offering.

According to the report, the global minimally invasive biopsy technologies market was valued at $924.8 million in 2018 and is anticipated to reach $4.03 billion by 2030. The global minimally invasive biopsy technologies market is expected to grow at a double-digit compound annual growth rate (CAGR) in the forecast period 2019-2030, aided primarily by the anticipated launch of novel minimally invasive biopsy technologies.

The rapidly growing incidences of cancer and other chronic inflammatory disorders are inciting the use of minimally invasive and real-time diagnostic methods for early detection. With better patient compliance and greater sensitivity, minimally invasive biopsy technologies such as liquid biopsy and optical biopsy are emerging as novel tools for the early detection and effective disease management. Additionally, several other technologies including brush biopsy, fine needle aspiration, breath biopsy, and pigmented lesion assays are considerably evolving to be used in the minimally invasive management of cancer.

The increasing adoption of targeted therapies and the growing prominence of the concept of personalized medicine is driving the adoption of minimally invasive biopsy technologies. The increasing adoption is further expected to bring down the cost and is expected to improve the patient access to these technologies.

North America is the leading contributor in the global minimally invasive biopsy technologies market and contributed approximately 62.06% to the global market value in 2018. This region is anticipated to grow at a CAGR of 11.25% during the forecast period 2019-2030 and to continue dominating the global market in 2030 as well. However, the European region is expected to grow at an impressive CAGR of 15.40% during the forecast period 2019-2030. The Asia-Pacific region contributed a share of 12.41% to the global market and is anticipated to grow at a CAGR of 14.65% during the forecast period 2019-2030.

Research Highlights

Optical biopsy expected to witness an impressive CAGR of 15.77% during the forecast period 2019-2030. Moreover, in terms of therapeutic application, prostate cancer is expected to witness an impressive growth at a CAGR of 14.97% during the forecast period 2019-2030.

Liquid biopsy is currently the largest shareholder in the global minimally invasive biopsy technologies market. This market dominance is largely attributed to the worldwide availability of a significant number of liquid biopsy technologies.

This market intelligence report provides a multi-dimensional view of the global minimally invasive biopsy technologies market in terms of market size and growth potential. This research report aims at answering various aspects of the global minimally invasive biopsy technologies market with the help of key factors driving the market, restraints that can possibly inhibit the overall growth of the market, and the current growth opportunities that are going to shape the future trajectory of the market expansion.

Furthermore, the competitive landscape chapter in the report explicates the competitive nature of the global market and enables the reader to get acquainted with the recent market activities, such as product launches and approvals, partnerships, collaborations, business expansions, as well as mergers and acquisitions. The research report provides a comprehensive analysis of the product sales, manufacturers, service providers, and trend analysis by segment, and growth share analysis by region. Additionally, the report provides a comprehensive attractive analysis and opportunity analysis for the entire global minimally invasive biopsy technologies market for 2018 and 2030.

This report is a meticulous compilation of the research of about 65 players in the market ecosystem and draws upon insights from in-depth interviews with the key opinion leaders of 9 leading companies, market participants, and vendors. The report also comprises 15 detailed company profiles including that of Abcodia Ltd., Adaptive Biotechnologies, Biocept, Inc., Caliber Imaging & Diagnostics, Chronix Biomedical, DermTech, F. Hoffmann-La Roche Ltd, Guardant Health, Inc., Mauna Kea Technologies, Myriad Genetics, NeoGenomics Laboratories, Inc., Owlstone Medical Ltd, QIAGEN, Thermo Fisher Scientific, and Veracyte, Inc.

The answers to the following key questions can be derived from this report:

Key Topics Covered

Executive Summary

1 Product Definition1.1 Inclusions and Exclusions

2 Research Scope2.1 Scope of Work2.2 Key Questions Answered in the Report

3 Research Methodology3.1 Global Minimally Invasive Biopsy Technologies Market: Research Methodology3.1.1 Primary Data Sources3.1.2 Secondary Data Sources3.1.3 Selection Criteria for Company Profiles

4 Industry Analysis4.1 Industry Ecosystem4.2 Regulatory Framework and Government Initiatives4.2.1 Liquid Biopsy: Regulatory Framework4.2.1.1 Liquid Biopsy: Regulations in the U.S.4.2.1.2 Liquid Biopsy: Regulations in Other Countries4.2.2 Optical Biopsy and Other Technologies: Regulatory Framework4.2.2.1 Optical Biopsy and Other Technologies: Regulations in the U.S.4.2.2.2 Optical Biopsy and Other Technologies: Regulations in Europe4.2.2.3 Optical Biopsy and Other Technologies: Regulations in Other Countries4.3 Patent Analysis4.3.1 Liquid Biopsy: Patent Analysis4.3.2 Optical Biopsy: Patent Analysis4.4 Physician's Perception

5 Competitive Landscape5.1 Key strategies and Developments5.1.1 Partnerships, Alliances, and Business Expansions5.1.2 New Offerings5.1.3 Funding Activities5.1.4 Procurement and Sales Agreements5.1.5 Regulatory and Legal Developments5.1.6 Mergers and Acquisitions5.2 Market Share Analysis5.2.1 Market Share Analysis: Global Liquid Biopsy Market5.2.2 Market Share Analysis: Global Optical Biopsy Market5.2.3 Market Share Analysis: Global Other Technologies Market5.3 Growth Share Analysis5.3.1 Growth Share Matrix (by Technology)5.3.2 Growth Share Matrix (by Therapeutic Application)5.3.3 Growth Share Matrix (by Region)

6 Global Minimally Invasive Biopsy Technologies Market, 2018-20306.1 Assumptions and Limitations6.2 Key Findings and Opportunity Assessment6.3 Global Minimally Invasive Biopsy Technologies, Market Scenario6.3.1 Global Minimally Invasive Biopsy Technologies Market Size and Forecast (2018-2030)6.3.2 Market Dynamics6.3.2.1 Overview6.3.2.2 Impact Analysis6.3.2.3 Market Drivers6.3.2.3.1 Rising Global Burden of Cancer6.3.2.3.2 Increasing Number of Cross-Industry Collaborations6.3.2.3.3 Growing Prominence of Precision Medicine6.3.2.4 Market Restraints6.3.2.4.1 Uncertain Regulatory Requirements6.3.2.4.2 Lack of Favorable Reimbursement Policies6.3.2.4.3 Technical Challenges Associated with the Analysis of Circulating Biomarkers6.3.2.5 Market Opportunities6.3.2.5.1 Business Expansion in Emerging Economies6.3.2.5.2 Integration of Artificial Intelligence (AI)6.3.2.5.3 Rising Number of Initiatives by the Government6.4 Market Estimation Method

7 Global Minimally Invasive Biopsy Technologies Market, by Technology, 2018-20307.1 Overview7.2 Global Liquid Biopsy Market Scenario, 2018-20307.2.1 Principle and Advantages of Liquid Biopsy7.2.2 Key Findings and Opportunity Assessment7.2.3 Global Liquid Biopsy Market, Market Size and Forecast (2018-2030)7.2.3.1 Market Dynamics7.2.3.1.1 Impact Analysis7.2.3.1.2 Market Drivers7.2.3.1.2.1 Increasing Demand for Liquid Biopsy Tests7.2.3.1.2.2 Recent Product Launches and Approvals7.2.3.1.2.3 Strong Pipeline7.2.3.1.3 Market Restraints7.2.3.1.3.1 Uncertain Regulatory Requirements7.2.3.1.3.2 Lack of Adequate Reimbursement7.2.4 Global Liquid Biopsy Market Segmentation7.2.4.1 Global Liquid Biopsy Market (by Product), 2018-20307.2.4.1.1 Overview7.2.4.1.2 Tests7.2.4.1.3 Kits and Consumables7.2.4.1.4 Instruments7.2.4.2 Global Liquid Biopsy Market, by Circulating Biomarker, Market Size and Forecast (2018-2030)7.2.4.2.1 Overview7.2.4.2.2 Circulating Tumor DNA (ctDNA)7.2.4.2.3 Circulating Tumor Cells (CTCs)7.2.4.2.4 Cell-Free DNA (cfDNA)7.2.4.2.5 Extracellular Vesicles and Others7.2.4.3 Global Liquid Biopsy Market, by Clinical Application, Market Size and Forecast (2018-2030)7.2.4.3.1 Overview7.2.4.3.2 Treatment Monitoring7.2.4.3.3 Prognosis and Recurrence Monitoring7.2.4.3.4 Treatment Selection7.2.4.3.5 Diagnosis and Screening7.2.4.4 Global Liquid Biopsy Market, by Therapeutic Application, Market Size and Forecast (2018-2030)7.2.4.4.1 Overview7.2.4.4.2 Lung Cancer7.2.4.4.3 Breast Cancer7.2.4.4.4 Prostate Cancer7.2.4.4.5 Colorectal Cancer7.2.4.4.6 Blood Cancer7.2.4.4.7 Other Types of Cancer7.2.4.4.8 Non-Oncology Applications7.3 Global Optical Biopsy Market Scenario, 2018-20307.3.1 Principle and Advantages of Optical Biopsy7.3.2 Key Findings and Opportunity Assessment7.3.3 Global Optical Biopsy Market, Market Size and Forecast (2018-2030)7.3.3.1 Market Dynamics7.3.3.1.1 Impact Analysis7.3.3.1.2 Market Drivers7.3.3.1.2.1 Recent Product Launches and Approvals7.3.3.1.2.2 Significant Number of Funding and Investments7.3.3.1.2.3 Anticipated Product Launches7.3.3.1.3 Market Restraints7.3.3.1.3.1 Lack of Favorable Reimbursement7.3.3.1.3.2 Stringent Regulatory Guidelines7.3.4 Global Optical Biopsy Market (by Therapeutic Application), 2018-20307.3.4.1 Overview7.3.4.2 Oncology7.3.4.3 Non-Oncology Applications7.4 Global Other Technologies Market Scenario, 2018-20307.4.1 Overview7.4.2 Key Findings and Opportunity Assessment7.4.3 Global Other Technologies Market, Market Size and Forecast (2018-2030)7.4.3.1 Market Dynamics7.4.3.1.1 Impact Analysis7.4.3.1.2 Market Drivers7.4.3.1.2.1 Ongoing Strategic Collaborations and M&A Activities7.4.3.1.2.2 Strong Product Pipeline7.4.3.1.3 Market Restraints7.4.3.1.3.1 Poor Reimbursement Scenario7.4.3.1.3.2 Limited Scope of Expansion in Emerging Economies7.4.4 Global Other Technologies Market, (by Therapeutic Application)7.4.4.1 Overview7.4.4.2 Lung Cancer7.4.4.3 Melanoma7.4.4.4 Thyroid Cancer7.4.4.5 Non-Oncology Applications

8 Global Minimally Invasive Biopsy Technologies Market, (by Region), 2018-20308.1 Overview and Key Findings8.2 North America8.3 Europe8.4 Asia-Pacific8.5 Latin America and the Middle East8.6 Rest-of-the-World

9 Company Profiles9.1 Abcodia Ltd.9.2 Adaptive Biotechnologies9.3 Biocept, Inc.9.4 Caliber Imaging & Diagnostics9.5 Chronix Biomedical9.6 DermTech9.7 F. Hoffmann-La Roche Ltd.9.8 Guardant Health, Inc.9.9 Mauna Kea Technologies9.10 Myriad Genetics9.11 NeoGenomics Laboratories, Inc.9.12 Owlstone Medical Ltd.9.13 QIAGEN9.14 Thermo Fisher Scientific9.15 Veracyte, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/3128v2

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-minimally-invasive-biopsy-technologies-markets-2019-2030---a-4-billion-opportunity-with-focus-on-liquid-biopsy-optical-biopsy-and-brush-biopsy-pigmented-lesion-assays-and-breath-biopsy-301035982.html

SOURCE Research and Markets

Read more:
Global Minimally Invasive Biopsy Technologies Markets, 2019-2030 - A $4+ Billion Opportunity with Focus on Liquid Biopsy, Optical Biopsy, and Brush...

Heading into this year, I was passionate about getting a very important message in front of investors.

Source: Shutterstock

It was my thesis that the next decade would not only be the most innovative in history, but that the stock market would experience its largest gains ever.

The start of 2020 as brutal as it has been reminds me of 1990. Stocks had already been in a bull market for eight years when the ball dropped on 1989 and ushered in the new decade. Most experts believed the bull market was over and that the 1990s would be a lost decade.

Boy, were they wrong.

The 1990s went on to become one of the greatest decades for stocks. Little technology companies youd never heard of became household names. Dell Computer now Dell Technologies (NYSE:DELL) gained over 91,000% during the 1990s. The biggest gains of the decade were driven by a plethora of new technologies centered around the internet and personal computing.

Today, we are now three months into the 2020s and stocks are in a similar situation. We entered the decade on the back of a 10-year bull market, only to slide quickly into a bear market.

Most people dont realize this, but the Dow did something similar in 1990. It fell by 19.5% essentially a bear market to start the decade before powering higher. I believe we will look back at the current sell-off and see it as the last great buying opportunity before a booming decade.

The selling is creating buying opportunities in investment trends that wont slow due to the pandemic. In fact, they could even accelerate due to the changing global landscape. Lets take a look at a few

Robotics:According to the editorial board atScience Robotics, robots could be an alternative to humans when it comes to certain healthcare tasks. Especially during a pandemic. Robots could collect lab results, automate lab tests, and help disinfect the patient rooms. In China, it was deemed too dangerous for humans to make critical deliveries of medicine and food into infected areas, so the country turned to robots.

Genomics:The future of healthcare will be based on advances in both technology and medicine. The latter will rely on the field of genomics. In the coming decade, it will be the norm to have your genome sequenced. This information will help create personalized medicine for each patient, as well as help speed up the creation of new drugs.

The response to the coronavirus is a great example of how medicine is evolving. In 10 years, this type of pandemic would not be an issue. The combination of artificial intelligence (AI), quantum computing, and genomics would create a vaccine within days.

Tele-everything:The biggest change to our lives throughout this ordeal has been the self-isolation. Either through a government mandate or by choice, most people around the globe are staying inside and not going about their normal activities. This has led to a work-from-home, school-from-home, and even workout-from-home situation.

The companies behind this trend are here to stay. When the pandemic is over, people will go back to work, school, and their local fitness facilities. But the tele-everything trend is not going away. In some circumstances, it is more convenient than what we were accustomed to. Everything from software companies to one of my favorite stocks,Teladoc (NYSE:TDOC), to online education will be pushed to grow faster and quicker after the pandemic.

Even though a lot of the stocks in these trends have been beaten down in the last month, the trends themselves are not dead. Nothing I mean nothing in life goes straight up. When it comes to the stock market, the strongest trends will hit speed bumps but those bumps offer investors opportunities.

Let me be straight with you. If you want to be wealthy, you must buy into high-growth, long-term trends. And to make the BIG money you need to buy when everyone else is selling.

That day is today.

Matthew McCall left Wall Street to actually help investors by getting them into the worlds biggest, most revolutionary trends BEFORE anyone else. The power of being first gave Matts readers the chance to bank +2,438% in Stamps.com (STMP), +1,523% in Ulta Beauty (ULTA) and +1,044% in Tesla (TSLA), just to name a few. Click here to see what Matt has up his sleeve now. Matt does not directly own the aforementioned securities.

More:
3 High-Growth Trends to Invest In Now - Investorplace.com

The current pandemic situation that the world is suffering due to the SARS-CoV-2 coronavirus is hopelessly transforming any forecast that would have been set for 2020 in most environments. Even more in the field of health, where efforts are being made to end this situation.

In the case of personalized medicine in Spain, this year they expected to solve technological, social, legal, ethical and healthcare challenges with the possible approval of a strategic plan by the Government, which has been analyzed by the Senate for more than two years with the collaboration of experts in the field. A long-awaited regulation that it is more than likely to delay again.

From the point of view of the investigation, advances were outlined in CRISPR / Cas9, a molecular tool to edit or correct the genome of a cell. Also in a more efficient and combined use of the so-called micas omics sciences: genomics, metabolomics, epigenomics, etc., which, even though they have been going for several years, are still at the dawn of their journey.

Companies like OncoDNA, a company specialized in precision medicine for the treatment and diagnosis of cancer, continue working to promote new advances in this last section. She has spent several years dedicated to carrying out genomic analysis of samples from cancer patients, tissue and blood (liquid biopsy), to offer more information on the genetic profile of each tumor to specialists and thus be able to determine the most appropriate therapy for the patient.

Over the past 12 months the number of genes analyzed has been expanded in their tests, arriving their OncoDEEP and OncoSTRAT & GO solid biopsy panels until 313 and even, combining tissue analysis with liquid biopsy in stage IV solid tumors. Incorporating new essential biomarkers to know the peculiarities that can occur in each patient.

Pending all the news

In the same way, researchers continue to be very aware of the different publications that are appearing in the most prestigious media in the world in the field of oncology to improve their services. An example of this were the changes adopted a few months ago in your OncoSTRAT & GO test.

This new version includes the study of germline mutations in the ATM, BRCA1 and BRCA2 genes, as well as other pathway genes involved in homologous recombination, which can also be treated with PARP inhibitors. A solution that is already available and that is especially useful in patients with ovarian, prostate, pancreas and triple negative breast cancer.

In laboratories, and with the collaboration of different hospitals and specialized cancer centers around the world, work is also being done on this combination of omics sciences, which could offer a much more individualized view of the molecular profile of each patient, thus improving their prospects of success against cancer. Even to turn them into an effective tool to predict and assume preventive intervention strategies.

More advances in big data

Processing large amounts of data it will also continue to be key in the field of personalized medicine. Increasingly, taking into account that the progressive evolution of the micas omics will require technologies that translate their results into a language understandable to healthcare professionals.

In the oncological case they begin to emerge computer applications capable of processing and translating in a very short time the large amount of genetic information that each genomic analysis offers us. As with OncoKDM, an intelligent online genomic interpretation platform that responds to the most immediate needs of oncologists, pathologists, and other specialists in molecular biology.

It is capable of bringing together all the information that has been collected about a patient, such as the results of any genomic technology, molecular pathology data or clinical information, analyzing and interpreting it effectively at a clinical and biological level in a few minutes. In this way, it facilitates the oncologists decision making when choosing the ideal therapy for the patient or searching for clinical trials available in their country of origin , explains Adriana Terrdez, director of OncoDNA in Spain and Portugal.

It is to be expected that solutions such as those of genomic tests or software and platforms for the processing and interpretation of genomic data continue to evolve in the future in order to improve cancer patient care and make the best decisions in each case. It is working day by day in order that the news arrive as soon as possible. Even in these uncertain times.

//

Visit link:
COVID-19 transforms the challenges of Personalized Medicine for 2020 - Explica

Technological advancements and scientific breakthroughs have propelled the assessment of pathogenesis and fostered precision medicine industry. Precision medicine has become instrumental in alleviating suffering pertaining to medical care, owing to unintended side effects resulting from one-size-fits-all approach.

Rapid transformation towards precision medicine is also believed to reduce the cost of treatment by doing away with inapt treatment plans. Precision medicine has become pivotal in leveraging doctors to select treatments based on a genetic understanding of the patient's disease and creating a personalized treatment plan.

Genetic laboratory industry is believed to be using processing power, data, science and operators to enhance the results for costly and debilitating diseases. In terms of technology, big data is touted to set the trend in precision medicine market as the technology enables more precision and tailoring compared to linking diverse data sets to showcase casual pathways. Dependence of precision medicine on big data has propelled the biomedical research.

Request sample copy of this report @ https://www.decresearch.com/request-sample/detail/671

Stakeholders have shown increased traction towards big data analytics for it complements clinical care and streamlines public health surveillance. Notably, big data has the ability to track and predict major outbreaks to boost public healthcare resources and disseminate healthcare message to patients using social media.

Profound deployment of sensing technologies has fared well for big data analytics. With soaring trend for implantable and wearing sensing has been in line with the increased bandwidth and improved microelectronics.

With the wealth of information to different disease, big data revolution has offered an opportunity to embrace AI and machine learning algorithms in the massive data set. Global Market Insights, Inc., predicts big data analytics market share to have been registered at 12% in 2019, citing influx of complex of data generating in healthcare sector.

Make Inquiry about this report @ https://www.decresearch.com/inquiry-before-buying/671

Recent advancements in technology indicate that stakeholders are increasingly using precision medicine in oncology. With neurological disorders being one of the leading causes of morbidity and disability globally, precision medicine has grown in significance. The disorder is expected to grow on the heels of increased life expectancy and population growth leading to economic burden and health issues.

Oncology has opened avenues for precision medicines as central nervous system (CNS) market share in 2019 was pegged at over 24%, mainly attributed to soaring prevalence of CNS disorders globally.

Use of precision medicine in healthcare IT companies will become more noticeable in the next five years owing to soaring demand for technologically advanced equipment for analysis, rapid integration and storage of patient data. In bid to push to the capabilities in data analysis, data acquisition, and analytics-based decision making, established technology players and startups are adopting precision medicine.

Several healthcare IT companies are offering operation and software tools for healthcare systems to adopt personalized medicine. Healthcare IT companies segment was pegged at around US$ 16 bn in 2019.

With the time ideal for disruption through strategic business model owing to changing healthcare dynamics, stakeholders are increasingly inclined towards infusing investment in MEA. Leading companies believe MEA to emerge as a prominent growth ground for the industry.

While massive data has been captured for advanced economies, dearth of data in African countries and most of the Gulf countries has signified the importance of precision medicine. Further, burgeoning population has also been one of the factors fueling growth in the region. MEA market was pegged at over USD 3.0 billion in 2019 and is estimated to expand at a CAGR of more than 10.0% during the forecast period.

View original post here:
Precision Medicine Market growth outlook with industry review and forecasts - GroundAlerts.com

According to a new report published by Proficient Market, titled, Global Biochip Market by Product Type (DNA Chips Market, Lab-On-A-Chip Market, Protein Chips Market & other) and by End-Users/Application (Biotechnology and Pharmaceutical Companies, Hospitals and Diagnostics Centers, Academic & Research Institutes & Other) Global Market Share, Forecast Data, In-Depth Analysis, and Detailed Overview, and Forecast, 2015 2027 The report has offered an all-inclusive analysis of the global biochip market taking into consideration all the crucial aspects like growth factors, constraints, market developments, top investment pockets, future prospects, and trends. At the start, the report lays emphasis on the key trends and opportunities that may emerge in the near future and positively impact the overall industry growth.

According to the report, Global Biochip Market in 2019 stood at USD 14 billion and is expected to reach USD 62.82 billion by 2027 growing at a CAGR of 20.63% from 2020 to 2027.

Get Free Sample PDF (including full TOC, Tables and Figures) of Biochip Market @ https://proficientmarket.com/sample/1183

A biochip is a collection of microarrays organized on a solid substrate, allowing thousands of complex biochemical reactions, to determine various biological data, for instance, decoding the genes in less time. The biochip-based analysis is primarily used for on-site diagnosis. Biochips also undergo other diagnostic applications such as microarray technique, microfluidic technologies, & biosensors. A biochip can also provide analytical data regarding organic molecules associated with the living organisms. It helps in identifying airborne toxins, environmental pollutants, gene sequences, & other biochemical constituents.

Biochip Market Key Players: The research study includes profiles of leading companies operating in the global biochip market. Key players profiled in the report include:

Abbott Laboratories Agilent Technologies PerkinElmer Inc. Fluidigm Corporation Illumina GE Healthcare Bio-Rad Laboratories Inc. Cepheid Inc. Thermo Fisher Scientific F. Hoffmann-La Roche AG.

Do enquire to get a strategic overview of the market, Access Research Methodology Prepared By Experts at: https://proficientmarket.com/buying-request/1183

Thermo Fisher Scientific Inc. completed the acquisition of Affymetrix Inc., a leading provider of cellular and genetic analysis products. This acquisition helped Thermo Fisher to strengthen its leadership in biosciences, as well as acquire new genetic analysis capabilities to better serve clinical and applied markets.

Drivers for the Global Biochip Market: The increased use of biochips due to increasing cancer treatment and diagnostics. Rise in personalized medicine, drug discovery and life science research, need for high speed diagnostics and increased government funding are some of the key factors driving the growth for global biochips market. In addition, increasing healthcare awareness is also fueling the growth of global biochips market. Thus all these factors led to boosting the growth of the biochips market.

Opportunities for the Global Biochip Market: Rapid growing application of biochips will drive the market growth during forecasted period. While the Technological advancements and new product launches in the market are witnessed to augment the growth of the biochips market in forthcoming years. However, Rising demand of biochips in developing countries is witnessed to increase the market share of biochips. Moreover the Increasing adoption of personalized medicines by households will also propel the growth of the biochips market. Thus, all these factors will provide lucrative opportunities for the growth of the biochips market.

Restrains for the Global Biochip Market: The Strict government regulatory guidelines related to biochips are hampering the growth of the market. While the High instrument costs will also restrain the growth of this market. Lack of proper knowledge about biochip technology is a prominent restraint lowering the demand for biochip products. The irregularities arriving in healthcare coverage around the world are also more likely to challenge the growth of biochips market. Variable cost and adoption of biochip technologies is likely to affect the personalisation of medicine, eventually lowering the revenues of the global biochips market. Thus all these factors are creating a negative impact at the growth of the biochip market.

Region Wise, Global Biochip Market Analysis: Report covers the region wise analysis, global Biochip market can be segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Among all, North America leads the global Biochip market share followed by Europe and Asia Pacific. While the North America leads the global Biochip market due to the factors such as presence of well-established players, advanced informatics infrastructure, presence of experts and skilled workforce, and ongoing genomic R & D practices on a large scale in the region. While the rising R & D investments in genomic research is driving the growth of the market. Moreover, growing awareness regarding genetic tests for disease risk assessment and prevention is anticipated to have a positive impact on the growth of the regional market..

Access Full Report, here: https://proficientmarket.com/report/1183/global-biochip-market

Global Biochip Market: Product analysisDNA Chips MarketGene ExpressionSNP GenotypingCancer Diagnosis & TreatmentGenomicsDrug DiscoveryAgricultural BiotechnologyLab-On-A-Chip MarketClinical DiagnosticsGenomicsIVD & POCProteomicsDrug DiscoveryProtein Chips MarketProteomicsExpression ProfilingDiagnosticsHigh-Throughput ScreeningDrug DiscoveryOther Cell ArraysTissue Arrays

On the basis of type DNA Chips Market, accounted for largest share of total revenue generated due to the increasing use of DNA chip products. The use of DNA chip has empowered the scientific community by enabling measurement of the expression levels of large numbers of genes simultaneously. A DNA chip involves an array of microscopic spots each carrying numerous single-stranded oligonucleotides and are widely being used in biomedical research activities. Thus due to its huge utilization led to the growth of this segment which is fueling the biochip market.

Global Biochip Market: Application analysisBiotechnology and Pharmaceutical CompaniesHospitals and Diagnostics CentersAcademic & Research InstitutesOther

The demand of Global Biochip Market is highest from Biotechnology and Pharmaceutical Companies due to the numerous features offered by it. The utilization rate of biochips in biotechnology and pharmaceutical companies was high. The hospitals & diagnostics is the second fastest growing segment due to the adoption of biochip in new drug discovery as well as in point-of-care diagnostics has increased the consumption of these biochips in hospitals & diagnostics centers. Thus all these factors led to increase usage of biochips in this sectors which is propelling the growth of the biochip market.

Global Biochip Market: Region analysisNorth America: U.S., Canada, MexicoEurope: U.K., France, Germany, Spain, Italy, Rest of EuropeAsia Pacific: China, Japan, South Korea, ASEAN, IndiaRest of Asia Pacific: Latin America, Brazil, Argentina, Colombia, Rest of L.A.Middle East and Africa: Turkey, GCC, UAE, South Africa, Rest of Middle East

The report can be customized as per client requirements. For further queries, you can contact us on [emailprotected] or +1-773-800-2974. Our executives will be pleased to understand your requirements and offer you the best-suited reports.

Read the full press release and latest news of this report, here: https://proficientmarket.com/press-release/1188/global-biochip-market

About Us:Proficient Market is the leading research company offering both tactical and strategic support to all our customers. Customer satisfaction is our goal and that is why, we have a team of skilled and experienced specialists with the ability to do data mining, information management, and revenue enhancement solutions to ensure that our clients make informed decisions when coming to investing in the market. Our happiness is when we help our clients grow their business, strengthen the brands and educate their members or consumers through the ever-new fun research methods developed by our team.

Contact Us:Proficient Market1st Floor, Harikrishna Building,Samarth Nagar, New Sanghvi,Pune- 411027 IndiaTel: +91-8149441100 (GMT Office Hours)USA: +17738002974Email: [emailprotected]Web: proficientmarket.com

This content has been distributed via WiredRelease press release distribution service. For press release service enquiry, please reach us at [emailprotected].

WiredRelease

Visit WiredRelease's Website

Here is the original post:
Insights On The Global Biochip Market To 2027 Featuring Abbott Laboratories, Agilent Technologies, PerkinElmer Inc., Fluidigm Corporation, Illumina,...

object(stdClass)#31465 (59) { ["id"]=> string(4) "5792" ["title"]=> string(69) "How Blockchain Improves Logistics: Benefits, Drawbacks, and Use Cases" ["alias"]=> string(66) "how-blockchain-improves-logistics-benefits-drawbacks-and-use-cases" ["introtext"]=> string(177) "

The blockchain technology and logistics industry tend to be quite profitable for each other. Additionally, this collaboration brings benefits to carriers and customers.

In this article, well discuss all you need to know about blockchain in the logistics sector.

Blockchain allows optimizing logistic processes in the real-time mode. This technology tends to improve the relationship between shippers and carriers.

We've singled out six main advantages of using blockchain in the logistics sector. Lets discuss them more precisely.

There are a lot of documents required for the transportation process. For example, a bill of lading or B/L. It stands for an agreement that consists of transportation terms, conditions, and other issues.

Blockchain allows recording all the steps. As a result, any participant can look through the delivery chain. If something happens, recorded information will report a problem.

Blockchain allows optimizing routes and delivering faster. In this case, smaller companies can compete with bigger ones, offering faster routes.

As a result, its possible to reduce expenses on the shipping process.

Blockchain simplified the process of goods certification. The combination of IoT and blockchain allows creating smart contracts.

Transactions made on blockchain are secure. Its impossible to change something in the transaction. It leads to decreasing fraudulent operations.

Intermediaries stand for agents that take part in the transportation chain. However, withlogistics software development, the industry doesnt need such specialists.

Weve already mentioned smart contracts. They tend to reduce time and expenses. Also, both parties have an opportunity to automate the validation process, manage obligations, and so on.

There were main blockchain advantages. As you can see, this technology can be quite profitable for the logistics industry.

Of course, there are some disadvantages of using blockchain technology. Lets discuss them more precisely.

Blockchain allows automating supply processes. As a result, there is no need for various specialists. The number of unemployed workers will rise.

Businesses that use blockchain technology should have a standard process. Unfortunately, these days, businesses dont have one.

Its required to create a standard process on the government level. So, businesses can follow it to avoid some common problems.

Its evident that blockchain development is expensive and time-consuming. Additionally, its required to have powerful hardware.

Also, there are expenses on specialists that are experienced in blockchain integration.

So, blockchain is a quite expensive technology that requires additional preparation before using it. However, some companies have already integrated blockchain and got some profit.

Blockchain makes it easy to track goods during shipment. Additionally, the companies have an opportunity to monitor the conditions of the packages.

As a result, its possible to detect broken goods, spoilt products, and so on.

Of course, such opportunities lead to decreasing unnecessary expenditures.

Successful story. Walmart cooperates with IBM to use the blockchain technology in the logistics. The system allows seeing what products are sold. Also, its possible to know the location of the product (the particular warehouse). The company claims that the supply process becomes more transparent.

Blockchain allows reducing the number of documents required for transportation. Additionally, the number of mistakes will also decrease due to automatization. The shipping terms fulfill more precisely.

Let's face it payments are important for any business. Blockchain makes this process secure. For example, its possible to make transactions with such cryptocurrencies as Bitcoin. As a result, the payment process is secure and transparent. Also, such solutions improve international processes.

Successful story. Tallysticks has made a platform that simplified payment processes using blockchain. The solution offers smart contracts that can be customized depending on the business needs and requirements.

Blockchain gives end consumers an opportunity to simplify the authenticity of the goods. There are platforms with data about product origin, quality, fineness, and others.

This technology gives clients transparency. As a result, people trust companies more.

Blockchain makes cooperation easier. For example, enterprises can cooperate with small companies to deliver goods faster. Such a solution is profitable for both parties.

These days, companies can cooperate with each other without intermediaries. It leads to cost reduction and improved delivery processes.

Successful story. ShipChain platform uses blockchain to improve cooperation. For instance, the service allows tracking the delivery from the warehouse to the buyer's door. It leads to better customer experience and satisfaction.

The delivery process is long and expensive. Also, there can occur various delays due to weather conditions and other issues.

Usually, to manage such issues, companies hire lawyers. However, blockchain changes the situation. The transportation process is tracked from the beginning to the end. So, both parties can see any changes in the route.

Also, the parties can monitor any issues connected to the delivery and decide whose fault they were.

Blockchain technology innovates the logistics sector. The companies can simplify the delivery process, making routes shorter.

All these solutions lead to customer satisfaction. As a result, the clients trust companies and order goods or services more often.

The main advantage of blockchain is transparency. Business owners, as well as end consumers, have an opportunity to track the delivery process. Also, customers can ensure that during the delivery the storing conditions were followed.

However, developing blockchain-based solutions is an expensive and time-consuming process. Companies have to prepare beforehand and single out the requirements of the final product.

Link:
The Growing Role of Artificial Intelligence in the Pharmaceutical Industry - BBN Times

According to the latest study conducted by Trends Market Research (TMR) the global market for precision medicine is anticipate grow manifold, reflecting a robust CAGR of over XX% during 2018 to 2025.

Rapid augmentation of the medicine industry across the globe will certainly benefit the global market forprecision medicine. In addition, factors such as growing infrastructural development, higher investments, streamlined drug approval systems along with companion diagnostics are expected to favor the overall market growth during the assessment period. Cost-effective DNA profiling and increasing prevalence of carcinogenic diseases worldwide are additional factors that are projected to propel the market growth. Moreover, apt storage of genome data is of great significance to the global market for precision medicine as demand for data medicare is on the rise. However, acute data storage capacity, data privacy breach and discrepancies in funding systems and hefty price tag of personalized drugs may deter the market growth in the near future.

Enquiry More About This Report:https://www.trendsmarketresearch.com/report/sample/3437

The global market for precision medicine has been categorized into various parent segments that are further segmented into smaller sub-divisions.

On the basis of technology, next-gen sequencing, bioinformatics and drug discovery technology are expected to be the technologies highlighting the expanding the market width in forthcoming years. Based on applications, the oncology segment is expected to witness an overwhelming growth and is estimated to reach US$ XX Billion over 2025, reflecting a staggering XX% CAGR. This is primarily owing to increasing prevalence of tumor-related disease amongst the global geriatric population. On the other hand, increasing cases of arthritis will favor the growth of immunology segment, which is expected to surpass US$ XX Million in revenues by 2025 end.

Vendor News

Key players operating in the global market for precision medicine include Eli Lilly And Company, Novartis AG, AstraZeneca and Laboratory Corporation of America Holdings. Most of the companies are implementing market strategies involving mergers, tie-ups and acquisitions. Increasing collaboration between healthcare and IT is expected to deliver fruitful gains to the market, expanding the overall business canvas for the stakeholders in the upcoming years.

Request For Report Discounts @ https://www.trendsmarketresearch.com/report/discount/3437

The popularity of precision medicine has grown significantly across various parts of the world, hence on the basis of region, the markets for precision medicine in Asia Pacific, North America, Europe, Latin America, and the Middle East and Africa (MEA) is set to achieve new figures of growth over the next eight years. Precisely, the market in North America is expected to present new lucrative opportunities, occupying over XX% share of the market during the forecast period. In addition, the region is estimated to surpass a market valuation of over US$ XX Million by the end of 2025.

The US and Canada will be the heavyweights of the global market owing to the existence of well-established medical industries in both the countries. In Europe, the market is expected to witness a steady growth and will increase its revenues charts close to US$ XX Million, riding on a healthy CAGR of over XX% during the assessment period. This is largely due to the increasing demand for precision medicines in countries such as France, UK, Italy and Germany. The Asia Pacific region is another region which is considered to be full of business potentials. The region is projected to increase at over XX% CAGR to reach approximately US$ XX Million by 2025 end. The market in APAC will be heavily dominated by Japan, while, India and China will compete for the second spot. Likewise, the in Latin America the market is expected to surge at a pace in terms of revenue over 2025. However, MEA will witness a sluggish growth of the market which is attributed to the lack of initiatives for conductive extensive research and development activities.

Make an Inquiry before [emailprotected] https://www.trendsmarketresearch.com/checkout/3437/Single

Visit link:
Precision Medicine Market to Witness a Healthy Growth during 2018-2025 - Curious Desk

Florida sees increased coronavirus tests and a surge in cases

The latest numbers show the state has tested about nine times more people for coronavirus than it did just a week ago. At the same time, the number of positive cases has surged. It makes sense that if you test more, youll find more coronavirus. But thats only a partial explanation for the swift rise in Covid-19 cases. USF Public Health Professor Jay Wolfson says the lack of testing up until now means that people who didnt know they were infected could have given the virus in a worst case -- to a thousand people in a week. [Source: Health News Florida]

Florida to allow recently retired health care workers to return to work

Gov. Ron DeSantis said Monday that he plans to sign an executive order allowing recently retired law enforcement and health care professionals to return to the workforce to help fight coronavirus. We need to have folks that are willing to return to service, DeSantis said. DeSantis said his order will allow recently retired law enforcement and health care personnel to return to work immediately. [Source: WESH]

Hotels could be used for medical surge

Health care facilities are preparing for the worst-case scenario: a medical surge that could overwhelm bed space inside hospitals. Some facilities are looking into other buildings and spaces that could be used to care for a large wave of COVID-19 patients. Dr. Stanley Marks, chief medical officer at Memorial Healthcare System in Broward County, talks about COVID-19 preparation efforts. [Source: WLRN]

Southwest Florida medical practice digests large growth plans

Lakewood Ranch physician Dr. Arun Khazanchi takes the future of the medical practice he leads, Florida Digestive Health Specialists, personally. As in personalized medicine. Like many physicians and health care providers, Khazanchi can see medicine is moving fast toward a world where biomarkers, genetic research and tailored treatments dominate health care no matter the payment system. [Source: Business Observer]

DeSantis orders Attorney General to investigate South Florida hospital

Florida Gov. Ron DeSantis called on the state attorney general Friday to investigate a South Florida hospital charging $150 per test for COVID-19, the disease caused by the novel coronavirus spreading rapidly across the state. While DeSantis did not name the hospital, Larkin Community Hospital operates a drive-thru testing site in Hialeah and charges $150 per test. [Source: WUSF]

ALSO AROUND FLORIDA:

What is a child health advocate in Florida? [NBC-2]From Gun safety to ATV safety, even sleep safety, child advocates at Golisano Childrens Hospital of Southwest Florida are focused on keeping children out of the hospital. A child advocate is somebody thats passionate about keeping kids safe in the community, whether that means one-on-one with the family, or one-on-one with kids, grandparents, said Sally Kreuscher, child advocacy program coordinator with Golisano Childrens Hospital.

Medical cannabis access an essential service sort of [The Lakeland Ledger]With nearly 328,000 Floridians officially registered as medical marijuana patients, the coronavirus has forced the states hand into declaring cannabis an essential component of health care. Unless, of course, youre a new patient in need of a card. In that case, you may be out of luck, for at least through the middle of next month.

Sarasota quilters sew face masks for health care workers [Sarasota Herald-Tribune]As the coronavirus pandemic mounts in the U.S. each day, the nation is facing a shortage of face masks for health care workers. The South Sarasota Modern Quilt Guild, like other sewing groups across the country, tapped into their talent to work on a solution. The guilds members have been busy at work for the past week sewing cotton face masks for health care professionals to wear on top of their disposable N95 masks.

Hillsborough among areas receiving hydroxychloroquine [WUSF]Hillsborough County is among the areas in Florida being hardest hit with coronavirus that will receive a shipment of hydroxychloroquine, a drug that is being touted by some as a possible treatment for the symptoms of coronavirus. During a news conference on Saturday, Gov. Ron DeSantis said he worked with David Friedman, the U.S. ambassador to Israel who he said he considers a friend -- to arrange the shipment from Israeli company Teva Pharmaceuticals.

Tags:Health Care eNews

Previous Health Care Updates:

View post:
Florida sees increased coronavirus tests and a surge in cases - Florida Trend

WASHINGTON: Researchers have created artificial proteins that can control the activity of genes and other molecules in living cells in predetermined ways, an advance that can be used to program the behaviour of more complex chemical and biological systems.

In the study, published in the journal Science, the scientists showed that the designer proteins can regulate the activity of genes inside the human immune system's T-cells, adding that the development may improve the safety and durability of future cell-based therapies.

The researchers, including those from the University of Washington in the US, explained that the proteins, like their electronic counterparts, logic gates, implement a Boolean function, which is a logical operation performed on one or more binary inputs that produces a single binary output.

They explained that these logic gates sense and respond to signals in predetermined ways.

Citing an example, the scientists said, the 'AND' gate produces output only when one input AND another are present.

When typing on a keyboard, pressing the Shift key AND the A key produces an uppercase letter A, they explained.

The novel protein logic gates, made from biological parts, aim to bring this level of control into bioengineered systems, the researchers added.

"Bioengineers have made logic gates out of DNA, RNA and modified natural proteins before, but these are far from ideal. Our logic gates built from de novo designed proteins are more modular and versatile, and can be used in a wide range of biomedical applications" said study senior author David Baker from the University of Washington.

Using proteins like the one currently developed, the scientists said, inputs such as the presence of two different molecules in a living cell can cause it to produce a specific output, such as activating or suppressing a gene.

"The whole Apollo 11 Guidance Computer was built from electronic NOR gates," said lead author Zibo Chen, a recent UW graduate student.

"We succeeded in making protein-based NOR gates. They are not as complicated as NASA's guidance computers, but nevertheless are a key step toward programming complex biological circuits from scratch," Chen added.

While recruiting a patient's own immune cells in the fight against cancer has worked for certain forms of the disease, targeting solid tumours with genetically engineered T-cells has proven challenging.

Based on earlier studies, the researchers believe this could in-part be due to T cell exhaustion.

Genetically altered T cells can fight for only so long before they stop working, they explained.

But with protein logic gates that respond to exhaustion signals, the scientists hope to prolong the activity of genetically modified T cells.

"Longer-lived T cells that are better programmed for each patient would mean more effective personalized medicine," Chen said.

Read the original:
Researchers develop novel 'smart' proteins programmed to turn genes on and off - Economic Times

DUBLIN, April 6, 2020 /PRNewswire/ -- The "Gut-on-a-Chip Market" report has been added to ResearchAndMarkets.com's offering.

The scope of this report is broad and covers various types of products available in the gut-on-a-chip market and the market's major geographical regions. Regions include North America, Europe, Asia-Pacific, and Rest of the World. The market size is estimated using data triangulation with both top-down and bottom-up approaches.

The market size was estimated by deriving the revenues of manufacturers. Revenue generated from the installation and maintenance of instruments has been excluded from this report.

This report explains the regional dynamics of the global market and regulatory scenario within the industry.

The report concludes with a special focus on the vendor landscape and includes detailed profiles of the major players in the global gut-on-a-chip market.

The report includes:

Key Topics Covered

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

Chapter 4 Market Analysis

Chapter 5 Market Breakdown by Application

Chapter 6 Market Breakdown by Region

Chapter 7 Regulatory Environment

Chapter 8 Competitive Landscape

Chapter 9 Company Profiles

Chapter 10 Recommendations and Conclusions

List of TablesSummary Table: Global Gut-on-a-Chip Market, by Region, 2018Table 1: Design Characteristics of Microfluidic Intestine ModelsTable 2: Global Gut-on-a-Chip Market, 2017 and 2018Table 3: Global Gut-on-a-Chip Market, by Application, 2018Table 4: Global Gut-on-a-Chip Market, by Region, 2018Table 5: Company Rankings in the Global Gut-on-a-Chip MarketTable 6: Beonchip: Product PortfolioTable 7: Beonchip: Recent Developments, 2018Table 8: Emulate Inc.: Product PortfolioTable 9: Emulate Inc.: Recent Developments, 2017-2019Table 10: Mimetas B.V.: Product PortfolioTable 11: Mimetas B.V.: Recent Developments, 2017-2019Table 12: TissUse GmbH: Product PortfolioTable 13: TissUse GmbH: Recent Developments, 2018 and 2019

List of FiguresSummary Figure: Global Gut-on-a-Chip Market Shares, by Region, 2018Figure 1: Global Organ-on-a-Chip Market Shares, 2018Figure 2: Global Gut-on-a-Chip Market Shares, by Application, 2018Figure 3: Global Gut-on-a-Chip Market Shares, by Region, 2018

For more information about this report visit https://www.researchandmarkets.com/r/ptwa46

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Visit link:
2020 Gut-on-a-Chip Industry Insights by Application & Region, Featuring Profiles of Beonchip, Emulate, Mimetas and Tissuse - PRNewswire

TOKYO--(BUSINESS WIRE)--CureApp, Inc. (Head Office, Chuo-ku, Tokyo; President and CEO, Kohta Satake, M.D.), developer of software as a medical device Digital Therapeutics mobile applications, has launched a Phase 3 multicenter, randomized comparative study (clinical trial) of "Digital Therapeutics for hypertension in Japan with various partners including Professor Kazuomi Kario, M.D., Ph.D., the Division of Cardiovascular Medicine, the Department of Medicine, and Jichi Medical University School of Medicine.

This study will evaluate the efficacy and safety of "Digital Therapeutics" in patients with essential hypertension who have not received an orally administered antihypertensive drug treatment. Patients will be divided into two groups; those using "Digital Therapeutics" in addition to lifestyle changes set according to the Guidelines for the Management of Hypertension 2019 (the "Guidelines) (*1), and those only adopting said lifestyle habit changes without using Digital Therapeutics. The primary criteria for evaluation is the change from the baseline in mean 24-hour systolic blood pressure*1 at 12 weeks after treatment begins, as measured by ambulatory blood pressure monitoring (ABPM)*2.

*1 Systolic blood pressure: Highest blood pressure in blood pressure measurement*2 Ambulatory blood pressure monitoring: Continuous measurement of blood pressure at certain intervals for 24 hours under normal lifestyle conditions. Blood pressure fluctuates due to various factors; this shows the daily variation in blood pressure (daily variation pattern).

Hypertension is the biggest risk factor for cerebrovascular and cardiovascular diseases (i.e. stroke, heart disease), and the annual death toll in Japan from these diseases attributed to hypertension is estimated to reach 100,000. The number of patients with hypertension in Japan is estimated approx. 43 million, and blood pressure is appropriately controlled in only 12 million of these patients (*1). The lifestyle improvements essential to hypertension treatment are difficult to sustain as they are largely dependent on a patients motivation or their workplace/home environment. At the same time, successful lifestyle intervention by medical institutions presents a challenge.

Under these circumstances, "Digital Therapeutics," a new treatment method utilizing mobile technology, aims to produce a strong therapeutic effect enabling patients to return to normal blood pressure and develop appropriate lifestyle habits by providing personalized, optimized treatment guidance to individual patients based on medical evidence and encouraging awareness/behavior changes. The hypertension treatment application used in this study will automatically analyze blood pressure and lifestyle characteristics of individuals from data that includes blood-pressure monitoring using a smart blood pressure monitor and lifestyle habit logs. This data will be used to provide optimal treatment guidance (advice on diet, exercise, sleep, etc., and information to encourage behavior improvements).

[Source](*1): The Guidelines for the Management of Hypertension 2019 [JSH2019], The Japanese Society of Hypertension (2019) https://www.jpnsh.jp/guideline.html

Professor Kazuomi Kario, M.D., Ph.D.Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine

Hypertension is the biggest risk factor for serious cardiovascular diseases such as stroke, myocardial infarction, and cardiac failure. Although thoroughgoing antihypertensive measures ensures to control these diseases, the control rate for hypertension in Japan is only about 30% at present. Reducing salt and alcohol intake, proper weight control, and exercise are very important in treating hypertension. However, these measures are difficult to maintain on a continual basis. Digital Therapeutics is the worlds first app to treat hypertension that provides full support for improving lifestyle habits directly lowering blood pressure by encouraging behavioral changes based on cognitive behavioral therapy. With its elaborate treatment program and the innovative application of new information technology, Digital Therapeutics assesses individual patients, and ensures an interactive information exchange between patients and physicians based on appropriate guidance with proven scientific evidence and patient behavior records. I hope to see this app serving as the first step toward realizing a self-cure of hypertension by closely monitoring the daily lives of individuals to help them improve their lifestyle habits.

Kohta Satake, M.D.President and CEO, CureApp, Inc.

The spread of Hypertension Digital Therapeutics as a treatment covered by health insurance will lead to preventing the progression of hypertension and inhibiting cardiovascular diseases. After this clinical trial, we aim to obtain regulatory approval and health insurance coverage. "Digital Therapeutics" can provide appropriate medical guidance to patients at home and outside the hospital, making it possible to provide high-quality personalized medical care to people of working age who find it difficult to make frequent visits to clinics, as well as people in remote areas. I feel certain that the increased use of "Digital Therapeutics," a new therapeutic approach using digital technology, will create new value in medical care for hypertension and contribute to reducing future medical costs.

About CureApp, Inc.

CureApp, Inc. is a MedTech start-up company that performs research and development and produces software as a medical device for disease treatments based on advanced software technology and medical evidence. CureApp pursues the research and development of "Digital Therapeutics, a disease treatment app, to establish a new form of medical service in Japan with a concept of an app that cures diseases.

"Digital Therapeutics" draws on a daily therapeutic process tailored to each patient to provide new therapeutic effects through analysis and guidance based on medical knowledge and evidence. Encouraging patients to improve their habits through raising their awareness and changing their behavior may also contribute to disease improvement. We clearly differentiate "Digital Therapeutics" app from the other unapproved healthcare applications as we aim to demonstrate the therapeutic effect of the "Digital Therapeutics" app in clinical studies, etc., obtain regulatory approval, and commercialize them as medical devices in the future. CureApp led the way in launching clinical studies of therapeutic application in Japan, and our first therapeutic application, Therapeutic Application for Nicotine Addiction," has completed clinical trials and is currently under application for regulatory approval. Development and clinical research on therapeutic applications for hypertension and NASH (non-alcoholic steatohepatitis) have also launched. We plan to leverage our U.S. subsidiary, which we founded last year, serve as a base of operations for broadly rolling out such "digital health solutions from Japan based on the model developed in Japan.

At present, the development status of "Digital Therapeutics" is as follows.

"Digital Therapeutics" is the registered trademark of CureApp, Inc.

General information of Jichi Medical UniversityName: Jichi Medical UniversityLocation: 3311-1 Yakushiji, Shimotsuke-shi, Tochigi-ken, JapanRepresentative: Toshio Oishi, Chairman of the BoardEstablished: February 1972URL: https://www.jichi.ac.jp/english/index.html

Corporate Profile of CureApp, Inc.Company Name: CureApp, Inc.President and CEO: Kohta Satake, M.D.Head Office Location: Kodenma-Cho YS Building 4th floor, 12-5, Nihonbashi Kodenma-Cho, Chuo-ku, Tokyo, JapanEstablished: July 31, 2014Business Description: Development of programmed medical devices, health-related mobile servicesURL: https://cureapp.co.jp/en/

See the original post:
Jichi Medical University and CureApp, Inc.: The First Phase 3 Clinical Trials of "Digital Therapeutics" for Hypertension Begin in Japan -...

By: New York Times | Published: April 2, 2020 10:59:26 pm On Saturday, the FDA took the unusual step of approving those drugs to treat hospitalized patients with coronavirus on an emergency basis, even though no significant clinical trials have yet been done.

Written by Katie Thomas

An experimental stem cell therapy derived from human placentas will begin early testing in patients with the coronavirus, a New Jersey biotech company said Thursday.

The treatment, being developed by the company Celularity, has not yet been used on any patients with symptoms of COVID-19, but it has caught the attention of Rudy Giuliani, President Donald Trumps personal lawyer. Giuliani recently featured an interview with the company founder on his website and said on Twitter that the product has real potential, while also criticizing the Food and Drug Administration for not moving more quickly to approve potential remedies.

There is no proven treatment for the respiratory disease, but several experimental approaches, including old malaria drugs and HIV antivirals, are being tested in patients around the world.

READ | Video from Japan shows how COVID-19 is getting transmitted through a third route

Celularity has also enthusiastically publicized the news of its early-stage trial for its treatment, known as CYNK-001. In an email Wednesday to a reporter, its public relations firm described a development as the first FDA approval for COVID-19 cell therapy. The agencys decision, however, merely gives a green light for its product to be used in a clinical trial, not widely prescribed to patients.

In recent weeks, the established scientific process of evaluating a drugs safety and effectiveness has been upended by Trump, who has repeatedly promoted the potential of two long-used malaria drugs that have shown mainly anecdotal evidence of helping patients. On Saturday, the FDA took the unusual step of approving those drugs to treat hospitalized patients with coronavirus on an emergency basis, even though no significant clinical trials have yet been done.

The early trial by Celularity which will primarily evaluate safety, as well as an initial look at efficacy will test its therapy in up to 86 patients with symptoms. They will receive infusions of the cell therapy in the hopes it will prevent them from developing the more severe form of the disease, Dr. Robert Hariri, Celularitys founder and chief executive, said in an interview Wednesday.

The objective here is preventative, Hariri said. If the timing of giving this can prevent those patients who have early disease from progressing to the more serious, life-threatening form, it could be a very, very useful tool.

The therapy involves using stem cells from the placenta known as natural killer cells that help protect a developing fetus or newborn from viruses that have infected the mother. Celularity has been testing these cells in cancer patients.

Hariri said the trial, which would not include a placebo control group, will take place at academic medical centers around the country. He said the company expected to see initial results about 30-60 days after the first patients receive their dose. If this study is successful, Hariri said, the company would move to a placebo-controlled study that would evaluate the drugs efficacy against the disease.

At least one outside expert said the approach could present safety risks. Paul Knoepfler, a stem cell researcher at the University of California, Davis, said that patients with coronavirus can develop severe reactions where their immune systems go too far in attacking cells in their lungs, causing damaging inflammation. Other cell therapies tested in China are designed to dampen the immune response. He said one risk with the natural killer cells is they could go in the other direction, exacerbating respiratory problems by massive killing of the patients respiratory cells.

Despite the scant evidence, Giuliani has become an early booster, interviewing Hariri on a podcast published on his website Saturday and praising the treatment on Twitter, saying, this therapy has real potential. In a tweet Saturday, he added, Lets hope FDA can recognize that their cumbersome process designed to keep us safer, if it is not altered dramatically in times of great need, can result in unimaginable loss of human life.

Around the same time, Twitter deleted a post by Giuliani that it said violated its rules. The tweet, from March 27, made unfounded claims about the malaria drug hydroxychloroquine, one of the treatments that Trump has supported.

Hariri said that he has known Giuliani for years and that the appearance on his podcast was a friendly chat between people who know each other and who share a common interest in this particular response to this disease.

He said that he has no business relationship with Giuliani, and that Giuliani is not representing him in any way, either paid or unpaid.

I dont have anything to do with what the mayor tweets or whatnot, and I dont agree or disagree with anything, he said.

Hariri said the company would follow the established process for testing whether a drug works.

We have waited for the FDA to complete their review, which they did in a heroic and quick fashion, he said.

On Wednesday evening the same day the FDA approved his trial Hariri praised the appearance by the agencys commissioner, Dr. Stephen Hahn, on the conservative Fox News talk show The Ingraham Angle.

We are fortunate to have Dr. Hahn at the helm, he tweeted.

The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest Coronavirus Outbreak News, download Indian Express App.

Read the original post:
Unproven Stem Cell Therapy Gets OK for Testing in Coronavirus Patients - The Indian Express

WASHINGTON, April 2, 2020 /PRNewswire/ -- An article published in Experimental Biology and Medicine (Volume 245, Issue 6, March 2020) (https://journals.sagepub.com/doi/pdf/10.1177/1535370220910690) examines the safety of stem cell therapy for the treatment of colon cancer.The study, led by Dr. J. Liu in the State Key Laboratory of Bioreactor Engineering and Shanghai Key Laboratory of New Drug Design at the East China University of Science and Technology in Shanghai (China), reports that mesenchymal stem cells from a variety of sources promote the growth and metastasis of colon cancer cells in an animal model.

Mesenchymal stem (MSCs), a category of adult stem cells, are being evaluated as therapy for numerous cancers.MSCs are excellent carriers for tumor treatment because they migrate to tumor tissues, can be genetically modified to secrete anticancer molecules and do not elicit immune responses.Clinical trials have shown that MSCs carrying modified genes can be used to treat colon cancer as well as ulcerative colitis. However, some studies have demonstrated MSCs can differentiate into cancer-associated fibroblasts and promote tumor growth.Therefore, additional studies are needed to evaluate the safety of MSCs for targeted treatment of colon cancer.

In the current study, Dr. Liu and colleagues examined the effects of mesenchymal stem cells (MSCs) from three sources (bone marrow, adipose and placenta) on colon cancer cells.MSCs from all three sources promoted tumor growth and metastasis in vivo. In vitro studies demonstrated that MSCs promote colon cancer cell stemness and epithelial to mesenchymal transition, which would enhance tumor growth and metastasis respectively.Finally, the detrimental effects of MSCs could be reversed by blocking IL-8 signaling pathways. Dr. Ma, co-author on the study, said that "Mesenchymal stem cells have a dual role: promoting and/or suppressing cancer. Which effect is dominant depends on the type of tumor cell, the tissue source of the MSC and the interaction between the MSC and the cancer cell. This is the major issue in the clinical application research of MSCs, and additional preclinical experimental data will be needed to evaluate the safety of MSCs for colon cancer treatment."

Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology & Medicine, said: "Lui and colleagues have performed elegant studies on the impact of mesenchymal stem cells (MSCs), from various sources, upon the proliferation, stemness and metastasis of colon cancer stem cells (CSCs) in vitro and in vivo. They further demonstrate that IL-8 stimulates the interaction between colon CSCs and MSCs, and activates the MAPK signaling pathway in colon CSCs.This provides a basis for the further study of MSCs as a biologic therapy for colon cancer."

Experimental Biology and Medicine is a global journal dedicated to the publication of multidisciplinary and interdisciplinary research in the biomedical sciences. The journal was first established in 1903. Experimental Biology and Medicine is the journal of the Society of Experimental Biology and Medicine. To learn about the benefits of society membership, visit http://www.sebm.org. For anyone interested in publishing in the journal, please visit http://ebm.sagepub.com.

Related Images

logo.png Logo

View original content to download multimedia:http://www.prnewswire.com/news-releases/stem-cell-therapy-for-colon-cancer-301033659.html

SOURCE Experimental Biology and Medicine

Read the rest here:
Stem Cell Therapy for Colon Cancer - Yahoo Finance

Dr. Bart Rademaker is announcing that he will host online classes on stem cell therapy and its impact on the coronavirus.

TAMPA, Fla., April 2, 2020 /PRNewswire-PRWeb/ -- Dr. Bart Rademaker, the long-time plastic surgeon who has branched out into stem cell therapy, is offering online classes to patients and doctors who are interested in learning more about regenerative medicine and the potential benefits on health in particular during this time with the coronavirus or COVID-19. Rademaker, has offered the therapy in his office for years and has been contacted by physicians and patients who wish to find out more information on the benefits it could have for those combating the virus as clinical trials are proceeding in many parts of the world.. The classes will be available beginning in April 2020 and include podcasts, blogs and other forms of information that are available online.

"The coronavirus has turned the world upside down and people are trying to gather any information they can. I've heard medical experts tell people to drink warm tea or water every 20 minutes. I've heard patients say they read that you can kill the virus with stem cell therapy. There is too much information going out there right now and I want to help patients and medical professionals get the facts on it. Based on my experience and my communication with experts in the field of regenerative medicine, I feel that I can offer some assistance." Dr. Bart Rademaker

One of the main things the doctor wishes to stress to people who are unsure how to minimize exposure is that they need to follow the guidelines put in place by their government and information provided on personal hygiene and safety. This includes washing hands thoroughly with water and soap rather than rely on hand soap. Trying to avoid contact with your eyes and mouth unless you've recently washed your hands. Taking vitamins to strengthen your immune system. Staying away from people and avoiding areas like grocery stores as long as possible are other good recommendations provided that people should follow.

"People are not sure what to do because the information comes at them so quickly. Even doctors are not sure when their patient asks them if stem cell therapy is a safe option to prevent or treat the coronavirus. When I have doctors calling me just because they saw that I offer regenerative medicine information online, I knew it was time to start getting aggressive with these classes and offer my assistance to everyone."

For more information you can call our team at: 727-748-7389

About Dr. Bart Rademaker

Dr. Bart Rademaker is based in Tampa, Florida and has over 20 years of experience as a well-respected medical professional. He has affiliations with several hospitals including Morton Plant and Mease Countryside. His degree is from Erasmus University Rotterdam Faculty of Medicine and added regenerative medicine to his practice four years ago.

SOURCE Dr. Bart Rademaker

See the rest here:
Dr. Bart Rademaker Offers Free Classes On Stem Cell Therapy And The Coronavirus - Yahoo Finance

SOUTH SAN FRANCISCO, Calif., April 02, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation(FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that Fluidigm CyTOF technology was used in a clinical study producing preliminary evidence that mesenchymal stem cell (MSC) therapy improves outcomes in patients with COVID-19 pneumonia, providing key information about potential mechanisms of action of the treatment strategy.

Results of the study, conducted by researchers in China, have been published in Aging and Disease.1

We used a 36-marker CyTOF panel to generate a broad immune profile of each patients peripheral blood before and after transplantation, said Wenjing Wang, PhD, Associate Professor at Beijing Hepatology Research Institute, Youan Hospital. Mass cytometry allowed us to look at all immune populations of interest in a single tube of peripheral blood mononuclear cells, enabling us to use less sample and to simplify our workflow and analysis.

The study, which evaluated clinical outcomes as well as changes in inflammatory and immune function for 14 days in seven patients with COVID-19 pneumonia, indicated that intravenous transplantation of MSCs was a safe and effective treatment for patients with COVID-19 pneumonia, including for those in severe condition.

Pulmonary function and symptoms of these seven patients were significantly improved within two days of MSC transplantation. Three of the patients, including one classified as severe, recovered and were discharged 10 days after treatment.

CyTOF analysis found that MSC treatment of severe cases led to disappearance in three to six days of overactivated cytokine-secreting immune cells and increases in regulatory T and dendritic cells. Importantly, there was a dramatic increase in a population of CD14+CD11c+CD11bmidregulatory dendritic cells, which may have helped to tamp down the cytokine storm associated with COVID-19 respiratory disease. Separate analysis of patient serum found significant reduction in levels of TNF-, a potent inflammatory cytokine, while IL-10, an anti-inflammatory cytokine, increased in the MSC treatment group compared to the placebo control group.

This level of new and valuable treatment research based on broad-based immune profiling is an important front in the COVID-19 fight, said Chris Linthwaite, President and CEO of Fluidigm. Fluidigm is actively engaged with many researchers in government and medical institutions who are addressing the COVID-19 pandemic from the perspectives of both immune profiling and virus detection and testing, and this study underscores the critical role that our technologies are playing in the global response to the outbreak.

In addition to our instruments, our assays and analysis software are increasingly the focus of customers in the global research community exploring immune profiling of COVID-19 infected populations. Our Maxpar Direct Immune Profiling Assay and Maxpar Pathsetter analysis software are a solution for labs seeking an easily deployed, fixed panel that can incorporate novel exploratory markers as well as standard markers, Linthwaite said.

We are inspired by this opportunity to provide meaningful tools in efforts to develop innovative solutions to this rapidly evolving pandemic.

About FluidigmFluidigm(FLDM) focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, and plant and animal research laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more information, visitfluidigm.com.

Fluidigm, theFluidigmlogo, CyTOF, Direct, Immune Profiling Assay, Maxpar, and Pathsetter are trademarks and/or registered trademarks ofFluidigm Corporationinthe United Statesand/or other countries. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.

Story continues

Forward-Looking Statements for FluidigmThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the implementation of Fluidigm microfluidics technology and products by third parties and the anticipated benefits of, and applications and demand for, such products. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to risks relating to the potential adverse effects of the coronavirus pandemic on our business and operating results during 2020; challenges inherent in developing, manufacturing, launching, marketing, and selling new products; risks relating to company research and development and distribution plans and capabilities; interruptions or delays in the supply of components or materials for, or manufacturing of, Fluidigm products; potential product performance and quality issues; intellectual property risks; and competition. Information on these and additional risks and uncertainties and other information affectingFluidigmbusiness and operating results is contained in Fluidigms Annual Report on Form 10-K for the year endedDecember 31, 2019, and in its other filings with theSecurities and Exchange Commission. These forward-looking statements speak only as of the date hereof.Fluidigmdisclaims any obligation to update these forward-looking statements except as may be required by law.

1 Leng, Z., Zhu, R., Hou, W. et al. Transplantation of ACE2 mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging and Disease 11 (2020): 216228.

Contacts:

Media:Mark SpearmanSenior Director, Corporate Communications650 243 6621mark.spearman@fluidigm.com

Investors:Agnes LeeVice President, Investor Relations650 416 7423agnes.lee@fluidigm.com

Read more here:
Fluidigm CyTOF Technology Used to Evaluate Stem Cell Therapy as a Potential Treatment for COVID-19 Pneumonia - Yahoo Finance

Nerve Repair and Regeneration market worldwide is projected to grow by US$7. 1 Billion, driven by a compounded growth of 12. 1%. Neurostimulation & Neuromodulation Devices, one of the segments analyzed and sized in this study, displays the potential to grow at over 12.

New York, April 02, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Nerve Repair and Regeneration Industry" - https://www.reportlinker.com/p05799212/?utm_source=GNW 3%. The shifting dynamics supporting this growth makes it critical for businesses in this space to keep abreast of the changing pulse of the market. Poised to reach over US$11.8 Billion by the year 2025, Neurostimulation & Neuromodulation Devices will bring in healthy gains adding significant momentum to global growth.

- Representing the developed world, the United States will maintain a 11% growth momentum. Within Europe, which continues to remain an important element in the world economy, Germany will add over US$339.2 Million to the regions size and clout in the next 5 to 6 years. Over US$405.8 Million worth of projected demand in the region will come from Rest of Europe markets. In Japan, Neurostimulation & Neuromodulation Devices will reach a market size of US$527.3 Million by the close of the analysis period. As the worlds second largest economy and the new game changer in global markets, China exhibits the potential to grow at 16.1% over the next couple of years and add approximately US$1.4 Billion in terms of addressable opportunity for the picking by aspiring businesses and their astute leaders. Presented in visually rich graphics are these and many more need-to-know quantitative data important in ensuring quality of strategy decisions, be it entry into new markets or allocation of resources within a portfolio. Several macroeconomic factors and internal market forces will shape growth and development of demand patterns in emerging countries in Asia-Pacific, Latin America and the Middle East. All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.

- Competitors identified in this market include, among others,

Read the full report: https://www.reportlinker.com/p05799212/?utm_source=GNW

NERVE REPAIR AND REGENERATION MCP13MARKET ANALYSIS, TRENDS, AND FORECASTS, FEBRUARY 2CONTENTS

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. GLOBAL MARKET OVERVIEW Nerve Repair and Regeneration Market Set for a Rapid Growth Neurostimulation and Neuromodulation Devices: Largest Product Segment Biomaterials to Exhibit Rapid Growth Nerve Repair and Regeneration Market by Application US and Europe Dominate the Market, Asia-Pacific to Register the Fastest Growth

2. FOCUS ON SELECT PLAYERS Abbott Laboratories, Inc. (USA) AxoGen, Inc. (USA) Boston Scientific Corporation (USA) Integra LifeSciences Corporation (USA) LivaNova, PLC (UK) Medtronic plc (USA) NeuroPace, Inc. (USA) Nevro Corporation.(USA) Orthomed S.A.S. (France) Polyganics B.V. (The Netherlands) Stryker Corporation (U.S.) Synapse Biomedical Inc. (U.S.) Synovis Micro Companies Alliance, Inc. (USA)

3. MARKET TRENDS & DRIVERS High Incidence of Brain Disorders and Nerve Injuries: Primary Market Driver EXHIBIT 1: Annual Incidence of Adult-Onset Neurologic Disorders in the US EXHIBIT 2: Symptomatic Epilepsy Incidence by Type (2019): Percentage Share Breakdown of Congenital, Degenerative, Infective, Neoplastic, Trauma, and Vascular Epilepsy EXHIBIT 3: Global Alzheimer's Prevalence by Age Group EXHIBIT 4: Diagnosed Prevalence Cases of Parkinsons Disease Across Select Countries Classification of Nerve Injuries Recent Developments in Spinal Cord Injury Treatment Rising Geriatric Population and Subsequent Growth in Prevalence Of Neurological Disorders EXHIBIT 5: Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2and 2050 Intensified Research Activity Across Various Neural Disciplines Induces Additional Optimism Stem Cell Therapy: A Promising Avenue for Nerve Repair and Regeneration New Biomaterials Pave the Way for Innovative Neurodegeneration Therapies Role of Nerve Conduits in the Treatment of Peripheral Nerve Injury Innovative Nerve Conduits from Stryker Technological Advancements and Product Innovations - A Key Growth Driver Neurostimulation Allows Paralyzed People to Regain Leg Movement Neurostimulator to Treat Neurological Conditions Micro-Implantable Solution for Neurostimulation Parasym Device for Neurostimulation Boston Scientifics Spinal Cord Stimulation Improves Quality of Life Intellis Platform Presents Smallest Implantable Neurostimulator Innovation in Deep Brain Stimulation for Parkinsons Disease Innovations in Spinal Cord Stimulation for Pain Smart Neuromodulation: The Combination of AI and Neuromodulation Technologies New Dynamic Lead Interface Design for Neurostimulator Devices Wireless SCS Neuromodulation Therapy: An Alternative to Traditional SCS System Select Recent Approvals of Neuro-stimulation and Neuromodulation Devices Select Launches in Spinal Cord Stimulation (SCS) Market Select Launches in Deep Brain Stimulation (DBS) Market Select Neurostimulation Devices in Clinical Trials Select Neuromodulation Devices in Clinical Trials

4. GLOBAL MARKET PERSPECTIVE Table 1: Nerve Repair and Regeneration Global Market Estimates and Forecasts in US$ Thousand by Region/Country: 2018-2025 Table 2: Nerve Repair and Regeneration Global Retrospective Market Scenario in US$ Thousand by Region/Country: 2009-2017 Table 3: Nerve Repair and Regeneration Market Share Shift across Key Geographies Worldwide: 2009 VS 2019 VS 2025 Table 4: Neurostimulation & Neuromodulation Devices (Product) World Market by Region/Country in US$ Thousand: 2018 to 2025 Table 5: Neurostimulation & Neuromodulation Devices (Product) Historic Market Analysis by Region/Country in US$ Thousand: 2009 to 2017 Table 6: Neurostimulation & Neuromodulation Devices (Product) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025 Table 7: Biomaterials (Product) Potential Growth Markets Worldwide in US$ Thousand: 2018 to 2025 Table 8: Biomaterials (Product) Historic Market Perspective by Region/Country in US$ Thousand: 2009 to 2017 Table 9: Biomaterials (Product) Market Sales Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025 Table 10: Neurostimulation & Neuromodulation Surgeries (Application) Global Market Estimates & Forecasts in US$ Thousand by Region/Country: 2018-2025 Table 11: Neurostimulation & Neuromodulation Surgeries (Application) Retrospective Demand Analysis in US$ Thousand by Region/Country: 2009-2017 Table 12: Neurostimulation & Neuromodulation Surgeries (Application) Market Share Breakdown by Region/Country: 2009 VS 2019 VS 2025 Table 13: Neurorrhaphy (Application) Demand Potential Worldwide in US$ Thousand by Region/Country: 2018-2025 Table 14: Neurorrhaphy (Application) Historic Sales Analysis in US$ Thousand by Region/Country: 2009-2017 Table 15: Neurorrhaphy (Application) Share Breakdown Review by Region/Country: 2009 VS 2019 VS 2025 Table 16: Nerve Grafting (Application) Worldwide Latent Demand Forecasts in US$ Thousand by Region/Country: 2018-2025 Table 17: Nerve Grafting (Application) Global Historic Analysis in US$ Thousand by Region/Country: 2009-2017 Table 18: Nerve Grafting (Application) Distribution of Global Sales by Region/Country: 2009 VS 2019 VS 2025 Table 19: Stem Cell Therapy (Application) Sales Estimates and Forecasts in US$ Thousand by Region/Country for the Years 2through 2025 Table 20: Stem Cell Therapy (Application) Analysis of Historic Sales in US$ Thousand by Region/Country for the Years 2009 to 2017 Table 21: Stem Cell Therapy (Application) Global Market Share Distribution by Region/Country for 2009, 2019, and 2025 Table 22: Hospitals & Clinics (End-Use) Global Opportunity Assessment in US$ Thousand by Region/Country: 2018-2025 Table 23: Hospitals & Clinics (End-Use) Historic Sales Analysis in US$ Thousand by Region/Country: 2009-2017 Table 24: Hospitals & Clinics (End-Use) Percentage Share Breakdown of Global Sales by Region/Country: 2009 VS 2019 VS 2025 Table 25: Ambulatory Surgery Centers (End-Use) Worldwide Sales in US$ Thousand by Region/Country: 2018-2025 Table 26: Ambulatory Surgery Centers (End-Use) Historic Demand Patterns in US$ Thousand by Region/Country: 2009-2017 Table 27: Ambulatory Surgery Centers (End-Use) Market Share Shift across Key Geographies: 2009 VS 2019 VS 2025

III. MARKET ANALYSIS GEOGRAPHIC MARKET ANALYSIS UNITED STATES Table 28: United States Nerve Repair and Regeneration Market Estimates and Projections in US$ Thousand by Product: 2018 to 2025 Table 29: Nerve Repair and Regeneration Market in the United States by Product: A Historic Review in US$ Thousand for 2009-2017 Table 30: United States Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 31: United States Nerve Repair and Regeneration Latent Demand Forecasts in US$ Thousand by Application: 2018 to 2025 Table 32: Nerve Repair and Regeneration Historic Demand Patterns in the United States by Application in US$ Thousand for 2009-2017 Table 33: Nerve Repair and Regeneration Market Share Breakdown in the United States by Application: 2009 VS 2019 VS 2025 Table 34: United States Nerve Repair and Regeneration Latent Demand Forecasts in US$ Thousand by End-Use: 2018 to 2025 Table 35: Nerve Repair and Regeneration Historic Demand Patterns in the United States by End-Use in US$ Thousand for 2009-2017 Table 36: Nerve Repair and Regeneration Market Share Breakdown in the United States by End-Use: 2009 VS 2019 VS 2025 CANADA Table 37: Canadian Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Thousand by Product: 2018 to 2025 Table 38: Canadian Nerve Repair and Regeneration Historic Market Review by Product in US$ Thousand: 2009-2017 Table 39: Nerve Repair and Regeneration Market in Canada: Percentage Share Breakdown of Sales by Product for 2009, 2019, and 2025 Table 40: Canadian Nerve Repair and Regeneration Market Quantitative Demand Analysis in US$ Thousand by Application: 2018 to 2025 Table 41: Nerve Repair and Regeneration Market in Canada: Summarization of Historic Demand Patterns in US$ Thousand by Application for 2009-2017 Table 42: Canadian Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 Table 43: Canadian Nerve Repair and Regeneration Market Quantitative Demand Analysis in US$ Thousand by End-Use: 2to 2025 Table 44: Nerve Repair and Regeneration Market in Canada: Summarization of Historic Demand Patterns in US$ Thousand by End-Use for 2009-2017 Table 45: Canadian Nerve Repair and Regeneration Market Share Analysis by End-Use: 2009 VS 2019 VS 2025 JAPAN Table 46: Japanese Market for Nerve Repair and Regeneration: Annual Sales Estimates and Projections in US$ Thousand by Product for the Period 2018-2025 Table 47: Nerve Repair and Regeneration Market in Japan: Historic Sales Analysis in US$ Thousand by Product for the Period 2009-2017 Table 48: Japanese Nerve Repair and Regeneration Market Share Analysis by Product: 2009 VS 2019 VS 2025 Table 49: Japanese Demand Estimates and Forecasts for Nerve Repair and Regeneration in US$ Thousand by Application: 2018 to 2025 Table 50: Japanese Nerve Repair and Regeneration Market in US$ Thousand by Application: 2009-2017 Table 51: Nerve Repair and Regeneration Market Share Shift in Japan by Application: 2009 VS 2019 VS 2025 Table 52: Japanese Demand Estimates and Forecasts for Nerve Repair and Regeneration in US$ Thousand by End-Use: 2018 to 2025 Table 53: Japanese Nerve Repair and Regeneration Market in US$ Thousand by End-Use: 2009-2017 Table 54: Nerve Repair and Regeneration Market Share Shift in Japan by End-Use: 2009 VS 2019 VS 2025 CHINA Table 55: Chinese Nerve Repair and Regeneration Market Growth Prospects in US$ Thousand by Product for the Period 2018-2025 Table 56: Nerve Repair and Regeneration Historic Market Analysis in China in US$ Thousand by Product: 2009-2017 Table 57: Chinese Nerve Repair and Regeneration Market by Product: Percentage Breakdown of Sales for 2009, 2019, and 2025 Table 58: Chinese Demand for Nerve Repair and Regeneration in US$ Thousand by Application: 2018 to 2025 Table 59: Nerve Repair and Regeneration Market Review in China in US$ Thousand by Application: 2009-2017 Table 60: Chinese Nerve Repair and Regeneration Market Share Breakdown by Application: 2009 VS 2019 VS 2025 Table 61: Chinese Demand for Nerve Repair and Regeneration in US$ Thousand by End-Use: 2018 to 2025 Table 62: Nerve Repair and Regeneration Market Review in China in US$ Thousand by End-Use: 2009-2017 Table 63: Chinese Nerve Repair and Regeneration Market Share Breakdown by End-Use: 2009 VS 2019 VS 2025 EUROPE Table 64: European Nerve Repair and Regeneration Market Demand Scenario in US$ Thousand by Region/Country: 2018-2025 Table 65: Nerve Repair and Regeneration Market in Europe: A Historic Market Perspective in US$ Thousand by Region/Country for the Period 2009-2017 Table 66: European Nerve Repair and Regeneration Market Share Shift by Region/Country: 2009 VS 2019 VS 2025 Table 67: European Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Thousand by Product: 2018-2025 Table 68: Nerve Repair and Regeneration Market in Europe in US$ Thousand by Product: A Historic Review for the Period 2009-2017 Table 69: European Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 70: European Nerve Repair and Regeneration Addressable Market Opportunity in US$ Thousand by Application: 2018-2025 Table 71: Nerve Repair and Regeneration Market in Europe: Summarization of Historic Demand in US$ Thousand by Application for the Period 2009-2017 Table 72: European Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 Table 73: European Nerve Repair and Regeneration Addressable Market Opportunity in US$ Thousand by End-Use: 2018-2025 Table 74: Nerve Repair and Regeneration Market in Europe: Summarization of Historic Demand in US$ Thousand by End-Use for the Period 2009-2017 Table 75: European Nerve Repair and Regeneration Market Share Analysis by End-Use: 2009 VS 2019 VS 2025 FRANCE Table 76: Nerve Repair and Regeneration Market in France by Product: Estimates and Projections in US$ Thousand for the Period 2018-2025 Table 77: French Nerve Repair and Regeneration Historic Market Scenario in US$ Thousand by Product: 2009-2017 Table 78: French Nerve Repair and Regeneration Market Share Analysis by Product: 2009 VS 2019 VS 2025 Table 79: Nerve Repair and Regeneration Quantitative Demand Analysis in France in US$ Thousand by Application: 2018-2025 Table 80: French Nerve Repair and Regeneration Historic Market Review in US$ Thousand by Application: 2009-2017 Table 81: French Nerve Repair and Regeneration Market Share Analysis: A 17-Year Perspective by Application for 2009, 2019, and 2025 Table 82: Nerve Repair and Regeneration Quantitative Demand Analysis in France in US$ Thousand by End-Use: 2018-2025 Table 83: French Nerve Repair and Regeneration Historic Market Review in US$ Thousand by End-Use: 2009-2017 Table 84: French Nerve Repair and Regeneration Market Share Analysis: A 17-Year Perspective by End-Use for 2009, 2019, and 2025 GERMANY Table 85: Nerve Repair and Regeneration Market in Germany: Recent Past, Current and Future Analysis in US$ Thousand by Product for the Period 2018-2025 Table 86: German Nerve Repair and Regeneration Historic Market Analysis in US$ Thousand by Product: 2009-2017 Table 87: German Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 88: Nerve Repair and Regeneration Market in Germany: Annual Sales Estimates and Forecasts in US$ Thousand by Application for the Period 2018-2025 Table 89: German Nerve Repair and Regeneration Market in Retrospect in US$ Thousand by Application: 2009-2017 Table 90: Nerve Repair and Regeneration Market Share Distribution in Germany by Application: 2009 VS 2019 VS 2025 Table 91: Nerve Repair and Regeneration Market in Germany: Annual Sales Estimates and Forecasts in US$ Thousand by End-Use for the Period 2018-2025 Table 92: German Nerve Repair and Regeneration Market in Retrospect in US$ Thousand by End-Use: 2009-2017 Table 93: Nerve Repair and Regeneration Market Share Distribution in Germany by End-Use: 2009 VS 2019 VS 2025 ITALY Table 94: Italian Nerve Repair and Regeneration Market Growth Prospects in US$ Thousand by Product for the Period 2018-2025 Table 95: Nerve Repair and Regeneration Historic Market Analysis in Italy in US$ Thousand by Product: 2009-2017 Table 96: Italian Nerve Repair and Regeneration Market by Product: Percentage Breakdown of Sales for 2009, 2019, and 2025 Table 97: Italian Demand for Nerve Repair and Regeneration in US$ Thousand by Application: 2018 to 2025 Table 98: Nerve Repair and Regeneration Market Review in Italy in US$ Thousand by Application: 2009-2017 Table 99: Italian Nerve Repair and Regeneration Market Share Breakdown by Application: 2009 VS 2019 VS 2025 Table 100: Italian Demand for Nerve Repair and Regeneration in US$ Thousand by End-Use: 2018 to 2025 Table 101: Nerve Repair and Regeneration Market Review in Italy in US$ Thousand by End-Use: 2009-2017 Table 102: Italian Nerve Repair and Regeneration Market Share Breakdown by End-Use: 2009 VS 2019 VS 2025 UNITED KINGDOM Table 103: United Kingdom Market for Nerve Repair and Regeneration: Annual Sales Estimates and Projections in US$ Thousand by Product for the Period 2018-2025 Table 104: Nerve Repair and Regeneration Market in the United Kingdom: Historic Sales Analysis in US$ Thousand by Product for the Period 2009-2017 Table 105: United Kingdom Nerve Repair and Regeneration Market Share Analysis by Product: 2009 VS 2019 VS 2025 Table 106: United Kingdom Demand Estimates and Forecasts for Nerve Repair and Regeneration in US$ Thousand by Application: 2018 to 2025 Table 107: United Kingdom Nerve Repair and Regeneration Market in US$ Thousand by Application: 2009-2017 Table 108: Nerve Repair and Regeneration Market Share Shift in the United Kingdom by Application: 2009 VS 2019 VS 2025 Table 109: United Kingdom Demand Estimates and Forecasts for Nerve Repair and Regeneration in US$ Thousand by End-Use: 2to 2025 Table 110: United Kingdom Nerve Repair and Regeneration Market in US$ Thousand by End-Use: 2009-2017 Table 111: Nerve Repair and Regeneration Market Share Shift in the United Kingdom by End-Use: 2009 VS 2019 VS 2025 SPAIN Table 112: Spanish Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Thousand by Product: 2018 to 2025 Table 113: Spanish Nerve Repair and Regeneration Historic Market Review by Product in US$ Thousand: 2009-2017 Table 114: Nerve Repair and Regeneration Market in Spain: Percentage Share Breakdown of Sales by Product for 2009, 2019, and 2025 Table 115: Spanish Nerve Repair and Regeneration Market Quantitative Demand Analysis in US$ Thousand by Application: 2018 to 2025 Table 116: Nerve Repair and Regeneration Market in Spain: Summarization of Historic Demand Patterns in US$ Thousand by Application for 2009-2017 Table 117: Spanish Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 Table 118: Spanish Nerve Repair and Regeneration Market Quantitative Demand Analysis in US$ Thousand by End-Use: 2to 2025 Table 119: Nerve Repair and Regeneration Market in Spain: Summarization of Historic Demand Patterns in US$ Thousand by End-Use for 2009-2017 Table 120: Spanish Nerve Repair and Regeneration Market Share Analysis by End-Use: 2009 VS 2019 VS 2025 RUSSIA Table 121: Russian Nerve Repair and Regeneration Market Estimates and Projections in US$ Thousand by Product: 2018 to 2025 Table 122: Nerve Repair and Regeneration Market in Russia by Product: A Historic Review in US$ Thousand for 2009-2017 Table 123: Russian Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 124: Russian Nerve Repair and Regeneration Latent Demand Forecasts in US$ Thousand by Application: 2018 to 2025 Table 125: Nerve Repair and Regeneration Historic Demand Patterns in Russia by Application in US$ Thousand for 2009-2017 Table 126: Nerve Repair and Regeneration Market Share Breakdown in Russia by Application: 2009 VS 2019 VS 2025 Table 127: Russian Nerve Repair and Regeneration Latent Demand Forecasts in US$ Thousand by End-Use: 2018 to 2025 Table 128: Nerve Repair and Regeneration Historic Demand Patterns in Russia by End-Use in US$ Thousand for 2009-2017 Table 129: Nerve Repair and Regeneration Market Share Breakdown in Russia by End-Use: 2009 VS 2019 VS 2025 REST OF EUROPE Table 130: Rest of Europe Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Thousand by Product: 2018-2025 Table 131: Nerve Repair and Regeneration Market in Rest of Europe in US$ Thousand by Product: A Historic Review for the Period 2009-2017 Table 132: Rest of Europe Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 133: Rest of Europe Nerve Repair and Regeneration Addressable Market Opportunity in US$ Thousand by Application: 2018-2025 Table 134: Nerve Repair and Regeneration Market in Rest of Europe: Summarization of Historic Demand in US$ Thousand by Application for the Period 2009-2017 Table 135: Rest of Europe Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 Table 136: Rest of Europe Nerve Repair and Regeneration Addressable Market Opportunity in US$ Thousand by End-Use: 2018-2025 Table 137: Nerve Repair and Regeneration Market in Rest of Europe: Summarization of Historic Demand in US$ Thousand by End-Use for the Period 2009-2017 Table 138: Rest of Europe Nerve Repair and Regeneration Market Share Analysis by End-Use: 2009 VS 2019 VS 2025 ASIA-PACIFIC Table 139: Asia-Pacific Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Thousand by Region/Country: 2018-2025 Table 140: Nerve Repair and Regeneration Market in Asia-Pacific: Historic Market Analysis in US$ Thousand by Region/Country for the Period 2009-2017 Table 141: Asia-Pacific Nerve Repair and Regeneration Market Share Analysis by Region/Country: 2009 VS 2019 VS 2025 Table 142: Nerve Repair and Regeneration Market in Asia-Pacific by Product: Estimates and Projections in US$ Thousand for the Period 2018-2025 Table 143: Asia-Pacific Nerve Repair and Regeneration Historic Market Scenario in US$ Thousand by Product: 2009-2017 Table 144: Asia-Pacific Nerve Repair and Regeneration Market Share Analysis by Product: 2009 VS 2019 VS 2025 Table 145: Nerve Repair and Regeneration Quantitative Demand Analysis in Asia-Pacific in US$ Thousand by Application: 2018-2025 Table 146: Asia-Pacific Nerve Repair and Regeneration Historic Market Review in US$ Thousand by Application: 2009-2017 Table 147: Asia-Pacific Nerve Repair and Regeneration Market Share Analysis: A 17-Year Perspective by Application for 2009, 2019, and 2025 Table 148: Nerve Repair and Regeneration Quantitative Demand Analysis in Asia-Pacific in US$ Thousand by End-Use: 2018-2025 Table 149: Asia-Pacific Nerve Repair and Regeneration Historic Market Review in US$ Thousand by End-Use: 2009-2017 Table 150: Asia-Pacific Nerve Repair and Regeneration Market Share Analysis: A 17-Year Perspective by End-Use for 2009, 2019, and 2025 AUSTRALIA Table 151: Nerve Repair and Regeneration Market in Australia: Recent Past, Current and Future Analysis in US$ Thousand by Product for the Period 2018-2025 Table 152: Australian Nerve Repair and Regeneration Historic Market Analysis in US$ Thousand by Product: 2009-2017 Table 153: Australian Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 154: Nerve Repair and Regeneration Market in Australia: Annual Sales Estimates and Forecasts in US$ Thousand by Application for the Period 2018-2025 Table 155: Australian Nerve Repair and Regeneration Market in Retrospect in US$ Thousand by Application: 2009-2017 Table 156: Nerve Repair and Regeneration Market Share Distribution in Australia by Application: 2009 VS 2019 VS 2025 Table 157: Nerve Repair and Regeneration Market in Australia: Annual Sales Estimates and Forecasts in US$ Thousand by End-Use for the Period 2018-2025 Table 158: Australian Nerve Repair and Regeneration Market in Retrospect in US$ Thousand by End-Use: 2009-2017 Table 159: Nerve Repair and Regeneration Market Share Distribution in Australia by End-Use: 2009 VS 2019 VS 2025 INDIA Table 160: Indian Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Thousand by Product: 2018 to 2025 Table 161: Indian Nerve Repair and Regeneration Historic Market Review by Product in US$ Thousand: 2009-2017 Table 162: Nerve Repair and Regeneration Market in India: Percentage Share Breakdown of Sales by Product for 2009, 2019, and 2025 Table 163: Indian Nerve Repair and Regeneration Market Quantitative Demand Analysis in US$ Thousand by Application: 2018 to 2025 Table 164: Nerve Repair and Regeneration Market in India: Summarization of Historic Demand Patterns in US$ Thousand by Application for 2009-2017 Table 165: Indian Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 Table 166: Indian Nerve Repair and Regeneration Market Quantitative Demand Analysis in US$ Thousand by End-Use: 2to 2025 Table 167: Nerve Repair and Regeneration Market in India: Summarization of Historic Demand Patterns in US$ Thousand by End-Use for 2009-2017 Table 168: Indian Nerve Repair and Regeneration Market Share Analysis by End-Use: 2009 VS 2019 VS 2025 SOUTH KOREA Table 169: Nerve Repair and Regeneration Market in South Korea: Recent Past, Current and Future Analysis in US$ Thousand by Product for the Period 2018-2025 Table 170: South Korean Nerve Repair and Regeneration Historic Market Analysis in US$ Thousand by Product: 2009-2017 Table 171: Nerve Repair and Regeneration Market Share Distribution in South Korea by Product: 2009 VS 2019 VS 2025 Table 172: Nerve Repair and Regeneration Market in South Korea: Recent Past, Current and Future Analysis in US$ Thousand by Application for the Period 2018-2025 Table 173: South Korean Nerve Repair and Regeneration Historic Market Analysis in US$ Thousand by Application: 2009-2017 Table 174: Nerve Repair and Regeneration Market Share Distribution in South Korea by Application: 2009 VS 2019 VS 2025 Table 175: Nerve Repair and Regeneration Market in South Korea: Recent Past, Current and Future Analysis in US$ Thousand by End-Use for the Period 2018-2025 Table 176: South Korean Nerve Repair and Regeneration Historic Market Analysis in US$ Thousand by End-Use: 2009-2017 Table 177: Nerve Repair and Regeneration Market Share Distribution in South Korea by End-Use: 2009 VS 2019 VS 2025 REST OF ASIA-PACIFIC Table 178: Rest of Asia-Pacific Market for Nerve Repair and Regeneration: Annual Sales Estimates and Projections in US$ Thousand by Product for the Period 2018-2025 Table 179: Nerve Repair and Regeneration Market in Rest of Asia-Pacific: Historic Sales Analysis in US$ Thousand by Product for the Period 2009-2017 Table 180: Rest of Asia-Pacific Nerve Repair and Regeneration Market Share Analysis by Product: 2009 VS 2019 VS 2025 Table 181: Rest of Asia-Pacific Demand Estimates and Forecasts for Nerve Repair and Regeneration in US$ Thousand by Application: 2018 to 2025 Table 182: Rest of Asia-Pacific Nerve Repair and Regeneration Market in US$ Thousand by Application: 2009-2017 Table 183: Nerve Repair and Regeneration Market Share Shift in Rest of Asia-Pacific by Application: 2009 VS 2019 VS 2025 Table 184: Rest of Asia-Pacific Demand Estimates and Forecasts for Nerve Repair and Regeneration in US$ Thousand by End-Use: 2018 to 2025 Table 185: Rest of Asia-Pacific Nerve Repair and Regeneration Market in US$ Thousand by End-Use: 2009-2017 Table 186: Nerve Repair and Regeneration Market Share Shift in Rest of Asia-Pacific by End-Use: 2009 VS 2019 VS 2025 LATIN AMERICA Table 187: Latin American Nerve Repair and Regeneration Market Trends by Region/Country in US$ Thousand: 2018-2025 Table 188: Nerve Repair and Regeneration Market in Latin America in US$ Thousand by Region/Country: A Historic Perspective for the Period 2009-2017 Table 189: Latin American Nerve Repair and Regeneration Market Percentage Breakdown of Sales by Region/Country: 2009, 2019, and 2025 Table 190: Latin American Nerve Repair and Regeneration Market Growth Prospects in US$ Thousand by Product for the Period 2018-2025 Table 191: Nerve Repair and Regeneration Historic Market Analysis in Latin America in US$ Thousand by Product: 2009-2017 Table 192: Latin American Nerve Repair and Regeneration Market by Product: Percentage Breakdown of Sales for 2009, 2019, and 2025 Table 193: Latin American Demand for Nerve Repair and Regeneration in US$ Thousand by Application: 2018 to 2025 Table 194: Nerve Repair and Regeneration Market Review in Latin America in US$ Thousand by Application: 2009-2017 Table 195: Latin American Nerve Repair and Regeneration Market Share Breakdown by Application: 2009 VS 2019 VS 2025 Table 196: Latin American Demand for Nerve Repair and Regeneration in US$ Thousand by End-Use: 2018 to 2025 Table 197: Nerve Repair and Regeneration Market Review in Latin America in US$ Thousand by End-Use: 2009-2017 Table 198: Latin American Nerve Repair and Regeneration Market Share Breakdown by End-Use: 2009 VS 2019 VS 2025 ARGENTINA Table 199: Argentinean Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Thousand by Product: 2018-2025 Table 200: Nerve Repair and Regeneration Market in Argentina in US$ Thousand by Product: A Historic Review for the Period 2009-2017 Table 201: Argentinean Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 202: Argentinean Nerve Repair and Regeneration Addressable Market Opportunity in US$ Thousand by Application: 2018-2025 Table 203: Nerve Repair and Regeneration Market in Argentina: Summarization of Historic Demand in US$ Thousand by Application for the Period 2009-2017 Table 204: Argentinean Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 Table 205: Argentinean Nerve Repair and Regeneration Addressable Market Opportunity in US$ Thousand by End-Use: 2018-2025 Table 206: Nerve Repair and Regeneration Market in Argentina: Summarization of Historic Demand in US$ Thousand by End-Use for the Period 2009-2017 Table 207: Argentinean Nerve Repair and Regeneration Market Share Analysis by End-Use: 2009 VS 2019 VS 2025 BRAZIL Table 208: Nerve Repair and Regeneration Market in Brazil by Product: Estimates and Projections in US$ Thousand for the Period 2018-2025 Table 209: Brazilian Nerve Repair and Regeneration Historic Market Scenario in US$ Thousand by Product: 2009-2017 Table 210: Brazilian Nerve Repair and Regeneration Market Share Analysis by Product: 2009 VS 2019 VS 2025 Table 211: Nerve Repair and Regeneration Quantitative Demand Analysis in Brazil in US$ Thousand by Application: 2018-2025 Table 212: Brazilian Nerve Repair and Regeneration Historic Market Review in US$ Thousand by Application: 2009-2017 Table 213: Brazilian Nerve Repair and Regeneration Market Share Analysis: A 17-Year Perspective by Application for 2009, 2019, and 2025 Table 214: Nerve Repair and Regeneration Quantitative Demand Analysis in Brazil in US$ Thousand by End-Use: 2018-2025 Table 215: Brazilian Nerve Repair and Regeneration Historic Market Review in US$ Thousand by End-Use: 2009-2017 Table 216: Brazilian Nerve Repair and Regeneration Market Share Analysis: A 17-Year Perspective by End-Use for 2009, 2019, and 2025 MEXICO Table 217: Nerve Repair and Regeneration Market in Mexico: Recent Past, Current and Future Analysis in US$ Thousand by Product for the Period 2018-2025 Table 218: Mexican Nerve Repair and Regeneration Historic Market Analysis in US$ Thousand by Product: 2009-2017 Table 219: Mexican Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 220: Nerve Repair and Regeneration Market in Mexico: Annual Sales Estimates and Forecasts in US$ Thousand by Application for the Period 2018-2025 Table 221: Mexican Nerve Repair and Regeneration Market in Retrospect in US$ Thousand by Application: 2009-2017 Table 222: Nerve Repair and Regeneration Market Share Distribution in Mexico by Application: 2009 VS 2019 VS 2025 Table 223: Nerve Repair and Regeneration Market in Mexico: Annual Sales Estimates and Forecasts in US$ Thousand by End-Use for the Period 2018-2025 Table 224: Mexican Nerve Repair and Regeneration Market in Retrospect in US$ Thousand by End-Use: 2009-2017 Table 225: Nerve Repair and Regeneration Market Share Distribution in Mexico by End-Use: 2009 VS 2019 VS 2025 REST OF LATIN AMERICA Table 226: Rest of Latin America Nerve Repair and Regeneration Market Estimates and Projections in US$ Thousand by Product: 2018 to 2025 Table 227: Nerve Repair and Regeneration Market in Rest of Latin America by Product: A Historic Review in US$ Thousand for 2009-2017 Table 228: Rest of Latin America Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 229: Rest of Latin America Nerve Repair and Regeneration Latent Demand Forecasts in US$ Thousand by Application: 2018 to 2025 Table 230: Nerve Repair and Regeneration Historic Demand Patterns in Rest of Latin America by Application in US$ Thousand for 2009-2017 Table 231: Nerve Repair and Regeneration Market Share Breakdown in Rest of Latin America by Application: 2009 VS 2019 VS 2025 Table 232: Rest of Latin America Nerve Repair and Regeneration Latent Demand Forecasts in US$ Thousand by End-Use: 2018 to 2025 Table 233: Nerve Repair and Regeneration Historic Demand Patterns in Rest of Latin America by End-Use in US$ Thousand for 2009-2017 Table 234: Nerve Repair and Regeneration Market Share Breakdown in Rest of Latin America by End-Use: 2009 VS 2019 VS 2025 MIDDLE EAST Table 235: The Middle East Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Thousand by Region/Country: 2018-2025 Table 236: Nerve Repair and Regeneration Market in the Middle East by Region/Country in US$ Thousand: 2009-2017 Table 237: The Middle East Nerve Repair and Regeneration Market Share Breakdown by Region/Country: 2009, 2019, and 2025 Table 238: The Middle East Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Thousand by Product: 2018 to 2025 Table 239: The Middle East Nerve Repair and Regeneration Historic Market by Product in US$ Thousand: 2009-2017 Table 240: Nerve Repair and Regeneration Market in the Middle East: Percentage Share Breakdown of Sales by Product for 2009, 2019, and 2025 Table 241: The Middle East Nerve Repair and Regeneration Market Quantitative Demand Analysis in US$ Thousand by Application: 2018 to 2025 Table 242: Nerve Repair and Regeneration Market in the Middle East: Summarization of Historic Demand Patterns in US$ Thousand by Application for 2009-2017 Table 243: The Middle East Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 Table 244: The Middle East Nerve Repair and Regeneration Market Quantitative Demand Analysis in US$ Thousand by End-Use: 2to 2025 Table 245: Nerve Repair and Regeneration Market in the Middle East: Summarization of Historic Demand Patterns in US$ Thousand by End-Use for 2009-2017 Table 246: The Middle East Nerve Repair and Regeneration Market Share Analysis by End-Use: 2009 VS 2019 VS 2025 IRAN Table 247: Iranian Market for Nerve Repair and Regeneration: Annual Sales Estimates and Projections in US$ Thousand by Product for the Period 2018-2025 Table 248: Nerve Repair and Regeneration Market in Iran: Historic Sales Analysis in US$ Thousand by Product for the Period 2009-2017 Table 249: Iranian Nerve Repair and Regeneration Market Share Analysis by Product: 2009 VS 2019 VS 2025 Table 250: Iranian Demand Estimates and Forecasts for Nerve Repair and Regeneration in US$ Thousand by Application: 2018 to 2025 Table 251: Iranian Nerve Repair and Regeneration Market in US$ Thousand by Application: 2009-2017 Table 252: Nerve Repair and Regeneration Market Share Shift in Iran by Application: 2009 VS 2019 VS 2025 Table 253: Iranian Demand Estimates and Forecasts for Nerve Repair and Regeneration in US$ Thousand by End-Use: 2018 to 2025 Table 254: Iranian Nerve Repair and Regeneration Market in US$ Thousand by End-Use: 2009-2017 Table 255: Nerve Repair and Regeneration Market Share Shift in Iran by End-Use: 2009 VS 2019 VS 2025 ISRAEL Table 256: Israeli Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Thousand by Product: 2018-2025 Table 257: Nerve Repair and Regeneration Market in Israel in US$ Thousand by Product: A Historic Review for the Period 2009-2017 Table 258: Israeli Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 259: Israeli Nerve Repair and Regeneration Addressable Market Opportunity in US$ Thousand by Application: 2018-2025 Table 260: Nerve Repair and Regeneration Market in Israel: Summarization of Historic Demand in US$ Thousand by Application for the Period 2009-2017 Table 261: Israeli Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 Table 262: Israeli Nerve Repair and Regeneration Addressable Market Opportunity in US$ Thousand by End-Use: 2018-2025 Table 263: Nerve Repair and Regeneration Market in Israel: Summarization of Historic Demand in US$ Thousand by End-Use for the Period 2009-2017 Table 264: Israeli Nerve Repair and Regeneration Market Share Analysis by End-Use: 2009 VS 2019 VS 2025 SAUDI ARABIA Table 265: Saudi Arabian Nerve Repair and Regeneration Market Growth Prospects in US$ Thousand by Product for the Period 2018-2025 Table 266: Nerve Repair and Regeneration Historic Market Analysis in Saudi Arabia in US$ Thousand by Product: 2009-2017 Table 267: Saudi Arabian Nerve Repair and Regeneration Market by Product: Percentage Breakdown of Sales for 2009, 2019, and 2025 Table 268: Saudi Arabian Demand for Nerve Repair and Regeneration in US$ Thousand by Application: 2018 to 2025 Table 269: Nerve Repair and Regeneration Market Review in Saudi Arabia in US$ Thousand by Application: 2009-2017 Table 270: Saudi Arabian Nerve Repair and Regeneration Market Share Breakdown by Application: 2009 VS 2019 VS 2025 Table 271: Saudi Arabian Demand for Nerve Repair and Regeneration in US$ Thousand by End-Use: 2018 to 2025 Table 272: Nerve Repair and Regeneration Market Review in Saudi Arabia in US$ Thousand by End-Use: 2009-2017 Table 273: Saudi Arabian Nerve Repair and Regeneration Market Share Breakdown by End-Use: 2009 VS 2019 VS 2025 UNITED ARAB EMIRATES Table 274: Nerve Repair and Regeneration Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Thousand by Product for the Period 2018-2025 Table 275: United Arab Emirates Nerve Repair and Regeneration Historic Market Analysis in US$ Thousand by Product: 2009-2017 Table 276: Nerve Repair and Regeneration Market Share Distribution in United Arab Emirates by Product: 2009 VS 2VS 2025 Table 277: Nerve Repair and Regeneration Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Thousand by Application for the Period 2018-2025 Table 278: United Arab Emirates Nerve Repair and Regeneration Historic Market Analysis in US$ Thousand by Application: 2009-2017 Table 279: Nerve Repair and Regeneration Market Share Distribution in United Arab Emirates by Application: 2009 VS 2019 VS 2025 Table 280: Nerve Repair and Regeneration Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Thousand by End-Use for the Period 2018-2025 Table 281: United Arab Emirates Nerve Repair and Regeneration Historic Market Analysis in US$ Thousand by End-Use: 2009-2017 Table 282: Nerve Repair and Regeneration Market Share Distribution in United Arab Emirates by End-Use: 2009 VS 2VS 2025 REST OF MIDDLE EAST Table 283: Nerve Repair and Regeneration Market in Rest of Middle East: Recent Past, Current and Future Analysis in US$ Thousand by Product for the Period 2018-2025 Table 284: Rest of Middle East Nerve Repair and Regeneration Historic Market Analysis in US$ Thousand by Product: 2009-2017 Table 285: Rest of Middle East Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 286: Nerve Repair and Regeneration Market in Rest of Middle East: Annual Sales Estimates and Forecasts in US$ Thousand by Application for the Period 2018-2025 Table 287: Rest of Middle East Nerve Repair and Regeneration Market in Retrospect in US$ Thousand by Application: 2009-2017 Table 288: Nerve Repair and Regeneration Market Share Distribution in Rest of Middle East by Application: 2009 VS 2019 VS 2025 Table 289: Nerve Repair and Regeneration Market in Rest of Middle East: Annual Sales Estimates and Forecasts in US$ Thousand by End-Use for the Period 2018-2025 Table 290: Rest of Middle East Nerve Repair and Regeneration Market in Retrospect in US$ Thousand by End-Use: 2009-2017 Table 291: Nerve Repair and Regeneration Market Share Distribution in Rest of Middle East by End-Use: 2009 VS 2019 VS 2025 AFRICA Table 292: African Nerve Repair and Regeneration Market Estimates and Projections in US$ Thousand by Product: 2018 to 2025 Table 293: Nerve Repair and Regeneration Market in Africa by Product: A Historic Review in US$ Thousand for 2009-2017 Table 294: African Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 295: African Nerve Repair and Regeneration Latent Demand Forecasts in US$ Thousand by Application: 2018 to 2025 Table 296: Nerve Repair and Regeneration Historic Demand Patterns in Africa by Application in US$ Thousand for 2009-2017 Table 297: Nerve Repair and Regeneration Market Share Breakdown in Africa by Application: 2009 VS 2019 VS 2025 Table 298: African Nerve Repair and Regeneration Latent Demand Forecasts in US$ Thousand by End-Use: 2018 to 2025 Table 299: Nerve Repair and Regeneration Historic Demand Patterns in Africa by End-Use in US$ Thousand for 2009-2017 Table 300: Nerve Repair and Regeneration Market Share Breakdown in Africa by End-Use: 2009 VS 2019 VS 2025

IV. COMPETITION

Total Companies Profiled:

Read the full report: https://www.reportlinker.com/p05799212/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

See the original post:
Global Nerve Repair and Regeneration Industry - Yahoo Finance

Welcome to FT Health, a monthly guide to the big issues at the intersection of global health and finance. Technology and investment are changing the face of healthcare while coronavirus is bringing an unprecedented focus on the worlds health systems. This newsletter delivers news, interviews, data and the best health journalism from across the web. Send us feedback at health@ft.com.

FT subscribers can sign up for the email versionhereand non- subscribershere.

Coronavirus: the dangers of distraction

Despite the intensifying globalisation of travel, trade and information in recent years, the current pandemic like those of the past shows that most countries only respond to an infection when it arrives on their doorstep. While health services are understandably focused on handling the surge of patients, the pandemic response highlights at least three risky distractions.

The first is the tension between short and long-term medical responses. While in most countries the current focus is on a lockdown of people to limit the spread of infection, along with urgently improving supplies of protection equipment, respirators and test kits for frontline workers, there is a need to start reflecting on an exit strategy.

As someresearchersare now arguing, efforts will need to escalate to differentiate between the most vulnerable and others who have survived infection and developed immunity, so they can return to essential work and support the economic recovery. Otherwise, the financial and associated health burden of poverty and isolation will end up being heavy. The models driving much of current policy do not considereconomic and ethicalfactors.

The second is the balance between coronavirus and existing burdensome illnesses. There are already reports of patients with cancer and other conditionsreceiving lower priority. High rates of childhood vaccination against preventable diseases will be difficult to sustain with prolonged social distancing. In lower-income countries, people with infections such as tuberculosis risk being turned away.

A final concern is the move away from international to domestic solidarity. Countries have closed borders, sought to restrict export of medical supplies and limited financial aid to their neighbours.But the neglect of international effortsto support or even focus on Africa and other poorer regions risks causing a disproportionatefinancial burden. In refugee camps, with scant medical support or even soap, thehuman tollcould be devastating.

To its credit, the Global Fund to Fight Aids, TB and Malaria has announcedup to 5 per centof its grants can be spent on Covid-19. More countries need to show similar solidarity to mitigate the damage to others or face the repercussions themselves.

Recommended links

Sir Alimuddin Zumla, Professor of Infectious Diseases and International Health, University College London, and joint guest editor of the International Journal of Infectious Diseasespecial issue on TB.

Following World TB Day, what progress and pitfalls do you see in tackling the disease?

We are moving forward, but very slowly. New drugs are being rolled out, with a simpler, shorter all-oral treatment, and Im optimistic well have a vaccine in 2-3 years time. We have seen political commitment fromthe presidents of Indonesia, Mozambique and the Philippines; the prime ministers of India and Pakistan andNigerias First Lady. I hope it is now backed by domestic fundingand their attention is not distracted by the Covid-19 pandemic.

How worried are you that coronavirus is proving a distraction?

Whole health services are now focused on Covid-19. Cancerpatients are having access problems. In Africa, we need to keep regular services afloat. Social distancing will make TB support challenging. Ministers are being politically pushed to respond because youve got to be seen to be doing something. But the best thing they can do is to make sure current services for TB, as well as HIV, malaria and maternal and child health, are not disturbedand Covid-19 is aligned to them.

Are there better ways to connect the medical response to TB and coronavirus?

There is a programme to expand TB GeneXpert diagnostics test equipment for coronavirus. Bothcause lethalrespiratory tract infections. People present with the same symptomsof cough, fever and breathlessness. We should take the opportunity to aligncommunitymessages and exploit synergiesin health services provisionincluding around diagnosis. With TB, as with Covid-19, we need to focus on the host, not the pathogen. For TB, that means tackling malnutrition, poverty, stress and poor living conditions.

Read more on the pandemics effect in our free-to-access collection of data and graphics. Heres an explainervideo on how we calculate the diseases trajectory.

Financing the crisis The IMF and World Bank are facing unprecedented demands from developing countries for help fighting coronavirus. The UN has called for a $2.5tn rescue package but the UN Security Council has been criticised for beingparalysed by theUS/China showdown over who was to blame for the disease spreading. Five world leaders wrote in the FT on the need for geopolitical turf wars to be set aside. (FT, Guardian, Foreign Policy, FT)

Chinas soft power After initial criticism of the way it handled the epidemic, China is keen to show itself as a responsible global power, sending doctors and masks overseas as its rates of domestic infections drop.

DRC: On life support The worlds biggest outbreak of measles in the Democratic Republic of Congo is one example of serious disease that has had little publicity in the shadow of Covid-19. A Unicef report highlights a health system struggling to cope with Ebola, cholera, malaria and measles amid ongoing armed conflict. (Al Jazeera, Unicef)

Safer surgery At least 42m people worldwide die within 30 days of surgery each year, and half of these deaths are in low- and middle-income countries. New surgical guidelines aim to save thousands of these lives, especially in the poorer countries that are disproportionately affected. (British Journal of Surgery)

Inequality in global healthThe new edition of theGlobal Health 50/50report says inequalities in power, privilege and priorities are undermining global health efforts. More than 80 per cent of those who lead the big international health organisations are from high-income countries and just five per cent are women from low- and middle-income countries. At the current rate of progress, gender parity in senior management will not be achieved until 2074. (Global Health 50/50)

Focus on...TBAs Sir Alimuddin Zumla notes in our interview above, progress on tackling diseases such as tuberculosis still the worlds top infectious killer could suffer from the worlds focus on Covid-19. The WHO says the preventive treatment agreed by world leaders in 2018 has fallen far short of its target. In that year alone, 10m people fell ill with TB and 1.5m lost their lives. TB also remains the top cause of death among people with HIV. Spending on TBin south-east Asia needs to be doubled from current levels to $2bn a year to make a serious attempt at ending the disease.As with coronavirus, young people remain key to prevention. (WHO, BMJ, The Conversation)

Hunt for coronavirus drugThe WHO and Unitaid, the UN-backed group funding global innovation, welcomed a proposal from Costa Rica for companies to pool intellectual property for all medical interventions, enabling governments or generic drugmakers to manufacture and sell at much lower prices. A therapeutics accelerator is giving $20m to speed drug trials.

Scientists are investigating three main types of drug: antiviralsto stop the virus from replicating; anti-inflammatories that treat the lungs after the immune system isoverwhelmed; and antibodies derived either from recovered Covid-19 patients or developed in labs, to be given to the seriously ill or as a temporary prophylactic for healthcare workers. (FT)

Vaccines and testsJohnson & Johnsonannounced a potential vaccine for Covid-19 that could be available early next year.The Coalition for Epidemic Preparedness Innovations is sponsoring severalvaccine projects, although Richard Hatchett, who heads this partnershipof governments, industry and charities, voiced fears about unequal access to treatment. He referredto the H1N1 flu in 2009, when the wealthiest countries secured contracts for deliveries of treatments that monopolised supplies. Tobaccocompanies are also getting involved. See too our guide to coronavirustesting.(FT, Devex)

Disease mappingAn innovative attempt at plugging health gaps in areas without detailed maps is blendingsatellite imagerywith machine-learning algorithms. (Devex)

Washing and sanitationIf theres one public health essential weve learned over the past few months, its the importance of washing your hands. But what if you dont have access to clean water? World Water Day this month was a time to remember that 40 per cent of the worlds people lack access to basic handwashing facilities at home, and 780m have no access to a quality water source. A UN reportsays climate change makes the goal of achieving access to safe drinking water and sanitation within ten years difficult. (Reliefweb, UN Water)

Tackling obesityChildhood obesity, recognised by the WHO as oneof the worlds most serious public health challenges,is linked to higher risk of anxiety, depression and premature death. People with obesity in childhood have a three-times higher risk of dying in early adulthood than their peers. An urban health foundation in London is taking a data-driven approach to tackling the problem. (PLoS Medicine, FT)

Combating diabetes Obesity is also a key driver of (Type-2) diabetes. An estimated four-fifths of diabetics, more than 336m people, live in lower- and middle-income countries, but there is no equivalent for the disease of the large-scale international support given to organisations such as the Global Fund to Fight Aids, TB and Malaria. Read the full FT report:Combating Diabetes

HIV hopes and fearsResearch has now been published on only the second HIV patientever to be cured of the disease, thanks to a stem cell transplant from donors with a HIV-resistant gene. Africanswith a disability are at much higher risk of HIV and less likely to receive treatment.Read how the discovery of HIV led to a transatlantic research war. (The Lancet HIV, Economist, PBS)

Fighting FGM UN targets to end female genital mutilation by 2030 are seriously off track, according to a coalition of global campaign groups. Unicef figures show FGM is inflicted on at least 200m women and girls in 31 countries, 27 of which are in Africa, and are likely to be grossly understated.(Equality Now)

Drug prices and UHCHigh medicine prices are a real threat to fledgling universal health coverage schemes. This study looks at the alternative ofvalue-basedtiered pricingwhich reflects both the ability of different countries to pay and the value that any medicine provides to local patients.

Children with cancer Some 11m children will die of cancer between now and 2050 without additional investment. The disease kills more than 100,000 children a year but 80 per cent of these cases are curable. Lowand middle-income countries where children have poor access to health services are disproportionately affected. (Lancet Oncology)

Climate change Heat stress, caused by the bodys inability to cool down properly through sweating, could affect more than 1.2bn people a year by 2100, says a new study more than four times the number affected today. Some want the WHO to declare climate change a global public health emergency. (Environmental Research Letters, BMJ)

Antibiotic alert A meta-study of antibiotic use shows three trends: city dwellers use more than those in rural areas; the elderly use more than the middle-aged, and usage decreases as education increases but only in rich countries. (International Journal of Hygiene and Environmental Health)

Coronavirus vaccine Seth Berkley, head of Gavi, the Vaccine Alliance, urges governments to set aside nationalism in the search for avaccine.(CBC, 13m)

The pandemic and the poorWhat does the coronavirus crisis mean for low-income countries and international development? A discussion with Amanda Glassman of the Center for Global Development.(UN Global Dispatches, 28m)

Urban healthHow do you build a healthy city? FT correspondents discuss initiatives in six cities, from tackling loneliness in Copenhagen to healthier eating in Tokyo.

Obamacare turns ten A discussion on the history, impact and prospects for the Affordable Care Act, which gave millions of Americans access to healthcare, but remains under threat. (Kaiser What the Health, 46m)

Epidemics in moviesWhat do films like Contagion tell us about societys view of epidemics? Some depict disease as a threat to society from outside, foreign forces, while others address threats to liberty, but both are linked to a breakdown in trust.(CDC Emerging Infectious Diseases, 32m)

April 7World Health Daycelebrating the work of nurses and midwives

April 14 FirstWorld Chagas Disease Day

April 19-20 G20 (virtual) meeting of health ministers, Riyadh

April 24-30 World Immunisation Week

April 25World Malaria Day

May 6 Next issue of FT Health

Contact Email us viahealth@ft.com, like us onFacebook and follow us on Twitter@fthealth andLinkedIn.

FT Health by email Register here to get FT Health in your inbox on the first Wednesday of each month.

Health at Work Join our quest to find Britains healthiest workplaces

Digital health Submit your ideasto the FT/Lancet Commission on how AI and digital health developments can benefit the worlds poorest.

FT resources You can find all FT in-depth health reports atFT Health Centre.

Coronavirus Business Update Sign upherefor our newsletter chronicling the epidemics impact on markets, global business, workplaces and our daily lives. The FT is offering a free 30-day trial to this email, which includes access to FT.com

Many short-term emergency measures will become a fixture of life. That is the nature of emergencies. They fast-forward historical processes, writesYuval Noah Hararion the world after coronavirus. The storm will pass. But the choices we make now could change our lives for years to come.

Read more:
FT Health: Coronavirus and the dangers of distraction - Financial Times